

Context-aware synthetic biology by controller design: engineering the mammalian cell

Nika Shakiba^{‡,† 1, 2}, Ross D. Jones^{‡,† 1, 2}, Ron Weiss^{1, 2, 3}, and Domitilla Del Vecchio^{1, 2, 4}

¹Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

²Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

³Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

⁴Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

[‡]These authors contributed equally.

[†]Current address: School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 2B9, Canada.

Lead contact: D.D.V. (ddv@mit.edu). Correspondence D.D.V., R.W. (rweiss@mit.edu), N.S. (nika.shakiba@ubc.ca), or R.D.J. (ross.jones@ubc.ca).

May 11, 2021

Abstract

The rise of the field of systems biology has ushered a new paradigm: the view of the cell as a system that processes environmental inputs to drive phenotypic outputs. Synthetic biology provides a complementary approach, allowing us to program cell behavior through the addition of synthetic genetic devices into the cellular processor. These devices, and the complex genetic circuits they compose, are engineered using a design-prototype-test cycle, allowing for predictable device performance to be achieved in a context-dependent manner. Within mammalian cells, context effects impact synthetic genetic device performance at multiple scales, including the genetic, cellular and extracellular levels. In order for synthetic genetic devices to achieve predictable behaviors, approaches to overcome context-dependence are necessary. Here, we describe control systems approaches for achieving context-aware devices that are robust to context effects. We then consider the application of cell fate programming as a case study to explore the potential impact of context-aware devices for regenerative medicine applications.

1 **The cell as a processor**

2 Cells are dynamic units of life that rely on microenvironmental cues to drive their decision-making. A cell's
3 behavior – to divide, die, move, or otherwise – is driven by social interactions with neighboring cells, binding to the
4 extracellular matrix (ECM), and by messages in the form of soluble signals. Whether a member of the multicellular
5 societies that compose our tissues or solo explorers in the unicellular world, each cell is a processor that must map
6 these dynamical chemical and mechanical inputs to phenotypic outputs (**Figure 1A**). Rooted in the field of systems
7 biology (Kauffman 1969; Milo et al. 2002; Barkai and Leibler 1997; Bhalla and Iyengar 1999; Hartwell et al. 1999)
8 the view of the cell as a processor offers a basis on which synthetic biology can build, manipulating cellular behavior
9 by engineering the processor.

10 The cell relies on an internal network that consists of molecular players (DNA, RNA, and proteins) that act in
11 concert with microenvironmental inputs to define "cell state". At any point in time, cell state can be captured by the
12 cellular transcriptome, proteome, epigenome and metabolome – the concentrations and chemical status of the cell's
13 molecular players. As in other dynamical systems, the current cell state is shaped by three critical elements: (1)
14 the inner regulatory network (the cell's processor), (2) inputs from the cell's microenvironment, and (3) the initial
15 state of the regulatory network itself. The rules that govern cell state are encoded in the cell's genome, which gives
16 rise to the RNA and proteins that take part in the regulatory network. Specifically, this network is composed of
17 dynamical processes (transcription, translation, and modifications to the molecular players in the network) that engage
18 in regulatory interactions with one another — a so-called "hairball". These interactions modulate the dynamical
19 processes in the cell. For example, transcription rates can be regulated through the binding of transcription factors
20 (TFs) to promoters; post-transcriptional regulation can involve RNA degradation by microRNA (miRNA); translation
21 rates can be influenced by modifications to messenger RNA (mRNA) untranslated regions (UTRs); post-translational
22 control can be achieved through modifications to protein stability; and epigenetic changes to the DNA itself can result
23 in compaction or methylation of regions of DNA (Del Vecchio and Murray 2014; Alberts et al. 2014; Alon 2019;
24 Allis et al. 2007). While 'omics strategies have been used to probe the transcriptome, proteome, epigenome, and
25 metabolome, they only offer a static image of the dynamic nature of the cell's regulatory network.

26 As a result of the starting cell state and environmental inputs that interact with receptors on the cell surface,
27 many cellular decisions, such as the fate of the cell, are made. Cellular decisions then shape phenotypic changes in
28 features, such as proliferation, death, morphology, polarity, metabolism, secreted factors, size, motility, and cell type
29 specification (Balázsi et al. 2011). Thus, one must consider the initial cell state as well as the cell's regulatory network
30 when predicting the impact of microenvironmental cues on a cell's phenotype. Cytokine pleiotropy – in which the
31 same soluble ligand inputs result in different phenotypic outcomes for cells, depending on the state of the cellular
32 processor (Nicola 1994; Sánchez-Cuenca et al. 1999) – provides an example for the impact of the initial cell state
33 on cellular decision-making. Consider, for example, the fibroblast growth factor (FGF) superfamily of cytokines,
34 which is known to exhibit strong action on a number of different cells, due to the diversity of interactions between
35 FGF ligands and their receptors (Kosaka et al. 2009). In the mouse, FGF-4 is first expressed in the inner cell mass
36 of the preimplantation mouse blastocyst. For these pluripotent mouse cells, microenvironmental FGF-4 drives cell
37 proliferation. However, the impact of FGF-4 on phenotypic outcomes changes as the cells in the developing mouse
38 embryo undergo specialization. Later in mouse development FGF-4 instead plays a role in directing mesenchymal
39 cell differentiation during tooth development. The ability of FGF-4 to drive different phenotypic outcomes is due to
40 changes in cell state as pluripotent cells undergo differentiation.

41 Cellular decision-making thus depends on the concentration and modification status of key molecular players, such
42 as DNA, RNA, and proteins, together determining cell state. It has been shown that the binding pattern of TFs differs
43 between cell types, suggesting that changes to the cellular epigenome can change regulatory processes in the cell,
44 allowing these processes to evolve over time as a function of accessibility of DNA binding domains and regulator
45 concentrations (Tsankov et al. 2015). TF and coactivator binding throughout the genome is a function of accessible
46 binding sites, where the relative binding affinity and concentration of competing binding partners determines the dom-
47 inant regulatory interactions (Hosokawa and Rothenberg 2020). Indeed, systems biology has demonstrated the utility
48 of modeling to better understand the impact of cell state on cellular decisions (Emmert-Streib et al. 2014; Davidson
49 and Peter 2015; Liu et al. 2018). These efforts have aimed to predict the phenotypic behaviors of cells, including
50 mammalian stem cells (Dunn et al. 2014; Kinoshita et al. 2018), by computationally modeling the cell's processor
51 and its initial state. Through the addition of microenvironmental inputs, cellular outcomes have been predicted using
52 models. These models can be augmented to yield probabilistic predictions of cellular outcomes by including different
53 sources of cellular noise (Quarton et al. 2020). In these stochastic models, fluctuations in biochemical reactions in-
54 volved in the dynamical processes and regulatory interactions within the cellular processor (Raser and O'Shea 2005)
55 serve as an additional stochastic input that influences cellular decision-making (Wilkinson 2009; Balázsi et al. 2011;
56 Zechner et al. 2020). To this end, combined experimental and computational techniques have helped to improve our
57 understanding of the molecular players in the cell's regulatory network.

58 In this review, we summarize the progress made by the field of mammalian synthetic biology, which adopts the sys-
59 tems biology view of the cell as a dynamical system, to program novel functions into the cellular processor (Khalil and
60 Collins 2010). Synthetic biology applies genetic engineering, mathematical modeling and computational approaches
61 to design and construct genetic circuits that produce predictable cellular outcomes. Many early genetic circuits were
62 developed in bacteria, including the toggle switch and oscillator (Gardner et al. 2000; Elowitz and Leibler 2000). Given
63 that cell state and the inner regulatory network are key drivers of cellular decision-making, the behaviors of synthetic
64 genetic circuits that are transplanted into cells are inevitably shaped by these drivers. Here, we specifically focus on
65 challenges that the mammalian cell context imposes, providing an overview of context effects that have important
66 implications for synthetic genetic device design. We then explore strategies involving control systems approaches
67 towards context-aware device design, with a particular emphasis on applications in cell fate programming.

68 **Cell fate programming: the promise of stem cells**

69 Owing to two cardinal properties – the ability to self-renew and to give rise to all of the cell types of the body –
70 pluripotent stem cells (PSCs) have generated excitement as a powerful substrate for regenerative medicine. Stem cell
71 potency has been conceptually visualized through the classic Waddington landscape (Waddington 1957). As cells roll
72 down the hills on the landscape, they lose their potential and commit to specialized cell types, which are epigenetically
73 stabilized in valleys that represent their endpoint fate (**Figure 1B**). The ability to reliably control the differentiation,
74 growth and death dynamics of stem cells and their progeny has been a key focus of stem cell bioengineers (Tewary
75 et al. 2018). Cell fate programming of PSCs to clinically relevant cell types has opened the door to new classes of
76 off-the-shelf cell therapies, in which viable cells are implanted into a patient in order to effectuate a medicinal effect.
77 Cellular therapies are a booming biotechnology industry, valued at over \$6 billion USD in 2020 and projected to reach
78 a global market share of \$9 billion by 2027 (Grand View Research report GVR-2-68038-701-8). They offer an exciting
79 paradigm shift towards the treatment of chronic and acute diseases through the transplantation of living cells and are a
80 compelling example of the clinical implications for mammalian synthetic biology.

81 Given that cells are dynamical systems whose outputs depend on microenvironmental cues, cell therapies open
82 the door to co-opting the native function of cells to deliver therapeutic function in a context- and site-specific manner
83 while allowing for regeneration of damaged tissues. A prime example of this is the advent of chimeric antigen receptor
84 (CAR) T cells, which demonstrate the ability to devise designer cells on-demand by engineering their function (June
85 et al. 2018). Specifically, CAR T cells are created by genetically engineering autologous (or patient-derived) T cells
86 to express a CAR specific to a target cell, such as B lymphocytes, allowing the engineered T cell to bind to and kill
87 aberrant cells like B cell lymphoblastic leukemia and lymphoma cells. The addition of the CAR to the T cell membrane
88 represents a relatively simple genetic maneuver that has profound impacts on the phenotypic function of the cell by
89 allowing a new environmental input to interface with the T cell's regulatory network. CAR T cells represent the tip of
90 the iceberg for how engineering of the cell's processor can unlock designer cells. Looking forward, synthetic biology
91 will allow for cell therapies to be genetically equipped with new functions – such as the ability to sense and kill cancer
92 cells (Rafiq et al. 2020) – while also offering a strategy for manufacturing allogeneic cell therapies through the efficient
93 directed differentiation of PSCs (Lee et al. 2020; Tewary et al. 2018; Prochazka et al. 2017).

94 The ability to reliably predict and program cellular decisions is a central goal in mammalian synthetic biology
95 (Kitaada et al. 2018; Prochazka et al. 2017; Ho and Chen 2017; Black et al. 2017; Xie and Fussenegger 2015; Lienert
96 et al. 2014). This capability is critical for both understanding how changes to the cell state and cellular inputs drive cell
97 fate changes, as well as for engineering cell-based therapies. Specifically, reliable programming of cellular functions
98 would have profound implications for our basic understanding of how genetic rules at the single cell level shape the
99 dynamics of multicellular systems, like our tissues and organs. It also opens the door to a new class of engineered cells
100 for therapeutic use, where synthetic genetic devices can be used to encode desired behaviors in cells in a predictable
101 and robust manner, both *in vitro* and post-transplantation (Kis et al. 2015; Kitaada et al. 2018; Tewary et al. 2018).

102 Despite their promise, PSC-derived cell therapies are not yet in prominent clinical use. A major barrier to the
103 translation of stem cell bioengineering efforts has been our inability to predictably and reproducibly control cell fate
104 changes. This includes challenges in guiding the trajectory of cells as they change from one cell type to another, such as
105 in the conversion of PSCs into specialized cell types, as well as challenges in controlling the cell-cell interactions that
106 shape the outcomes of multicellular populations. Synthetic biology offers a unique opportunity to redirect trajectories
107 of seemingly committed cell fates by opening up new channels and routes on the Waddington landscape (**Figure 1C**).
108 Cell fate control applications exemplify the potential impact of synthetic biology for programming mammalian cells
109 and is featured as a case study in this review.

110 **Cell fate programming: views from inside and outside of the cell**

111 Recognizing that both environmental inputs and the cellular processor influence cell fate trajectories, cellular
112 engineering has involved both niche and genetic engineering (Tewary et al. 2018). Genetic engineering approaches to
113 cell fate programming represent an "inside-out" approach, where portions of the cellular processor are manipulated:
114 either the receptors and signaling pathways (pathway engineering) or the regulatory networks themselves (regulatory
115 gene network engineering). Niche engineering, on the other hand, represents an "outside-in" approach, where the
116 cellular microenvironment is programmed through the addition of native or synthetic extracellular signals such as
117 cytokines, small molecules, and engineered cellular matrices (**Figure 2**). These environmental cues provide chemical
118 and mechanical inputs into the cellular processor, thus driving phenotype. Indeed, niche engineering strategies that
119 guide the differentiation trajectory of stem cells has been inspired by our expanding knowledge of the spatiotemporal

120 microenvironmental cues that shape embryonic development, which can be mimicked *in vitro* to give rise to specialized
121 cell types on demand (Keller 2005; Williams et al. 2012; Zhu and Huangfu 2013). Stem cell bioengineering has
122 focused on guiding the trajectory and outcome of these cells as they transition between fates. For example, human
123 pluripotent stem cells (PSCs) can be successfully differentiated to a beta cell state through a 7-stage protocol, where
124 each stage introduces cells to media containing a careful concoction of soluble factors (Rezania et al. 2014). The
125 staged addition of extracellular signals, which act as cellular inputs, can help guide cells on a trajectory of changing
126 cell fate.

127 Outside-in and inside-out engineering represent complementary approaches, as exemplified by recent advances in
128 cell fate programming through genetic engineering. Indeed, the foundational work of Yamanaka and Takahashi chal-
129 lenged the field’s perception of the programmability of the cellular processor by demonstrating the ability of inside-out
130 engineering to break the boundaries of cell fate plasticity (Takahashi and Yamanaka 2006). Through the overexpres-
131 sion of four key endogenous TFs (Oct4, Sox2, Klf4, c-Myc), fibroblasts were reprogrammed to pluripotency, moving
132 cells up the Waddington landscape and allowing them to stabilize in an induced PSC (iPSC) state through the pres-
133 ence of key cytokines in the microenvironment. This technically simple genetic manipulation, which perturbs the
134 expression rates of core pluripotency genes and morphs the Waddington landscape in a way that has not been achieved
135 through niche engineering efforts alone, showcases the power to engineer cell fate by targeting the cellular processor
136 (Del Vecchio et al. 2017; Zhou and Huang 2011; Huang et al. 2007). Reprogramming cell fate through the forced
137 overexpression of key genes unlocked the gateway for inside-out cell fate programming and lays the groundwork for
138 synthetic biology approaches to enter the stem cell bioengineering arena.

139 The degree to which synthetic biology can be used to program the cellular processor can vary (**Figure 2**). CAR T
140 cells represents an example of pathway engineering, where an engineered receptor interfaces with existing downstream
141 cellular machinery. On the other hand, cell fate programming involves the manipulation of the core regulatory network,
142 representing genetic engineering, allowing us to reprogram the cell’s identity – a property that was historically thought
143 to be rigid. Through the development of synthetic biology tools, we have the potential to allow the cell to traverse
144 novel fate trajectories that may otherwise not be achievable through outside-in approaches alone, and to do so in a
145 predictable manner. Future prospects for synthetic biology in mammalian cell programming also include the addition
146 of synthetic regulatory networks (circuits) that allow for novel processing capabilities in cells. A preliminary example
147 of novel cellular states is the derivation of so-called “fuzzy” iPSCs, which were derived through forced overexpression
148 of key TFs. Fuzzy iPSCs have the ability to give rise to cells in all three germ layers while exhibiting the resilience
149 to survive in the absence of cellular neighbors, making them an attractive potential substrate for suspension-based cell
150 manufacturing pipelines (Tonge et al. 2014). While the derivation of fuzzy iPSCs did not involve the use of genetic
151 circuits, the ability to derive a novel PSC state (that has not been observed naturally) through genetic manipulation
152 provides further motivation for the implications of synthetic biology in cell fate programming. Through synthetic
153 biology, inside-out engineering provides an avenue to direct cellular decisions, programming new functions into cells
154 and efficiently acquiring existing and novel target cell states for downstream applications.

155 **The genetic device as the core unit of synthetic biology**

156 Synthetic genetic devices are the basic dynamical unit that can be used to engineer the cellular processor (**Figure**
157 **3A**). Through the application of engineering principles, such as from dynamical systems and control theory (Åström

158 and Murray 2008; Del Vecchio and Murray 2014), it has been possible to achieve circuits with desired temporal
159 dynamics in gene expression and dose response (Gardner et al. 2000; Elowitz and Leibler 2000). Indeed, a key aspect
160 of synthetic biology is the aim to design and construct genetic circuits by wiring genetic devices together in a manner
161 to achieve desired input/output (I/O) temporal responses (Yosef and Regev 2011; Ang et al. 2013).

162 Given that the genetic device is the core unit of genetic circuits, careful attention should be paid to its design and
163 characterization. A basic genetic device includes a single transcriptional unit whereby a promoter drives the expression
164 of a coding sequence that is flanked by UTRs. The genetic device is composed of four key dynamical processes:
165 transcription, post-transcriptional regulation, translation, and post-translational regulation (**Figure 3B**). Transcription
166 is the process that generates mRNA from DNA; post-transcriptional changes to mRNA include processes such as
167 mRNA degradation; translation is the process that produces protein from mRNA; and post-translational changes to
168 proteins include processes, such as protein degradation or post-translational modification (*i.e.*, phosphorylation). The
169 rates of each of these processes are shaped by the values of physical parameters that can be used for design (**Figure**
170 **3C**). For example, the transcription rate can be tuned by the choice of promoter (Ede et al. 2016; Ponjavic et al.
171 2006; Haberle and Stark 2018) and terminator (Proudfoot 2016; Cheng et al. 2019), while the translation rate can
172 be tuned by the sequence in the 5' and 3' UTRs (De Nijs et al. 2020) (such as with the addition of binding sites for
173 endogenous miRNAs (Gam et al. 2018; Michaels et al. 2019)). Similarly, protein degradation can be tuned by adding
174 protein degradation domains (Trauth et al. 2019). These choices, being hard-coded in the DNA, represent static design
175 parameters that cannot be manipulated once the genetic device is constructed.

176 Each of the processes can be further regulated by suitable inputs, which can change with time (**Figure 3D**). For
177 example, the rate of transcription can be dynamically modulated by recombinases (Weinberg et al. 2017) and TFs
178 (Gaber et al. 2014; Kiani et al. 2014; Nissim et al. 2014; Stanton et al. 2014; Li et al. 2015; Donahue et al. 2020;
179 Israni et al. 2021); the rates of mRNA translation or degradation can be modulated by small molecules/aptamers
180 (Yokobayashi 2019), ribosome binding proteins (RBPs) (Wroblewska et al. 2015; Wagner et al. 2018; DiAndreth et al.
181 2019), and miRNAs (Cottrell et al. 2017; Michaels et al. 2019); and protein degradation and activity levels can be
182 modulated by proteases (Cella et al. 2018; Gao et al. 2018), engineered protein-protein interactions (Langan et al.
183 2019; Chen et al. 2020), and post-translational modifications (Prabakaran et al. 2012).

184 Finally, each genetic device has the molecular species it produces as outputs: RNA and protein. These can, in
185 turn, function as input regulators for other genetic devices, allowing circuit designers to wire genetic devices together
186 through output-to-input connections. The elements enumerated above thus serve as basic parts for building genetic
187 devices and regulating their functions, and can be composed together to make sophisticated genetic devices, such as
188 the control systems that we describe later. The degree to which such elements can be composed together depends on
189 the degree of context-dependence in their functions, which we discuss in more detail in the next section.

190 During the earliest days of the mammalian synthetic biology field, genetic devices were connected in simple
191 ways to derive desired functionality, including oscillators, memory, and digital logic gates (Khalil and Collins 2010;
192 Kitaada et al. 2018). Since then, the field has developed complex circuits composed of increasing numbers of devices
193 that are inter-connected to give rise to more sophisticated functions such as multi-input classification (Xie et al. 2011;
194 Prochazka et al. 2014), cell-cell communication (Johnson et al. 2017; Kojima et al. 2020), and directed development
195 (Guye et al. 2016; Prochazka et al. 2017), among other possibilities (Black et al. 2017; Kitaada et al. 2018).

196 Given that the genetic device, and the circuits that it constitutes, are embedded in a cell and the cell, in turn, is
197 influenced by its extra-cellular context (**Figure 4**), the properties of a synthetic genetic circuit will often vary with

198 respect to those initially prescribed. In order to facilitate robust and predictable behaviors of synthetic genetic circuits,
199 design-prototype-test (Khalil and Collins 2010) cycles can be achieved in mammalian cells by applying optimized
200 transfection pipelines that allow for quick and easy multifactorial quantification of device properties (Gam et al. 2019).
201 Specifically, modular cloning is a key tool that enables rapid prototyping of genetic device designs (Lienert et al.
202 2014). Nevertheless, the design-prototype-test approach can involve lengthy iterative processes due to poorly known
203 context effects, often with poor outcomes wherein a circuit's function is conditioned to specific intra- and extra-cellular
204 contexts. These contexts, however, are difficult to control in most realistic applications of mammalian synthetic genetic
205 circuits. In the next section, we describe known sources of uncertainty coming from the cellular context and introduce
206 solutions proposed to make genetic devices insulated from specific context effects.

207 **Challenges of context-dependent gene expression in mammalian cells**

208 Applications of synthetic biology to cell therapies, regenerative medicine, and beyond, all critically require key
209 challenges from the mammalian context to be addressed before we can achieve robust and predictable control of cell
210 behavior. Ideally, we could engineer cell behavior like a computer program, stitching together increasingly complex
211 functions and modules until we achieve the desired phenotype. However, this form of bottom-up design, which is a
212 bedrock of other engineering disciplines, is challenged by the unique environments inside and outside of cells and by
213 the properties of the programming substrate itself: nucleic acids. In any engineered system, whether it be mechanical,
214 electrical, or biological, there is always a discrepancy between the desired and actual system behaviors. Most of the
215 reasons for this discrepancy can be classified into three basic types: uncertainty in the values of physical parameters,
216 unmodeled dynamics, and externally acting perturbations that cannot be directly controlled or anticipated. Specific
217 to the biological substrate, uncertainty in the values of physical parameters can be orders of magnitude larger than
218 found in mechanical or electrical systems, the extent of dynamics that remain unmodeled in the design process is
219 substantial, and, most of all, the number and strength of unforeseen external perturbations acting on the engineered
220 system is unprecedented (Del Vecchio and Murray 2014). These external perturbations arise from the *context* (genetic,
221 cellular, and extracellular) in which the genetic device is placed (**Figure 5A**). Each perturbation affects certain rates
222 of the processes within genetic devices (**Table 1**), and thus influences observed emergent behaviors, ranging from
223 the operation of one cell to the phenotype of an entire tissue. In the following sections, we describe in greater detail
224 these perturbations that act on the genetic device by adopting a control systems view of the problem, wherein context
225 perturbations are depicted as disturbance inputs to the synthetic genetic device.

226 **Genetic context: perturbations from the local DNA environment**

227 As its name implies, the “genetic context” encapsulates the immediate genetic environment of the device (**Figure**
228 **5B,C**). Within mammalian cells, there are four main factors to consider with respect to genetic context. The first
229 factor is the genetic substrate. In most cases, genetic devices are encoded in DNA, though it is also possible to encode
230 programs in RNA (Beal et al. 2014; Wroblewska et al. 2015; Wagner et al. 2018). The second factor is the localization
231 of the substrate within the cell. Specifically, DNA-encoded devices are generally integrated into the genome or kept
232 outside of the genome within the nucleus, as in episomes (Ehrhardt et al. 2008). The position within the genome can
233 have substantial effects on gene expression, especially across cell types (Mitchell et al. 2004). RNA-encoded devices
234 may move among the nucleus, cytoplasm, and/or specialized compartments in the cellular membrane, depending on

Rate	Context effect
Transcription (α)	<ul style="list-style-type: none"> • Off-target TF activity • Gene copy number • Genomic integration site • Transcriptional resource availability • DNA torsion • DNA epigenetic state • Nearby enhancers/silencers
mRNA decay (δ)	<ul style="list-style-type: none"> • Off-target miRNA, ribonuclease, & deadenylase activity • RNA sequence and chemical modifications • mRNA localization • mRNA degradation resource availability • Change in dilution due to cell growth rate
Translation (β)	<ul style="list-style-type: none"> • Off-target miRNA & RBP activity • RNA sequence and chemical modifications • mRNA localization • Translational resource availability • Codon usage • UTR sequences
Protein decay (γ)	<ul style="list-style-type: none"> • Off-target protease activity • Covalent modifications • Protein localization • Protein degradation resource availability • Cell growth rate
PTMs (φ)	<ul style="list-style-type: none"> • Off-target kinase, phosphatase, & ubiquitin ligase activity • Covalent modifications • Protein localization • Protein co-factors

Table 1: Effect of context on gene expression and function

235 the type of RNA (Beal et al. 2014; Ryder and Lerit 2018). The third factor is how the encoding DNA or RNA is
236 replicated (or not) within the cell and propagated across progeny during cell divisions. Genomically-integrated DNA
237 is naturally replicated with the cell's genome and thus inherited by cellular progeny, but episomal DNA and RNA
238 require special sequences and proteins to be replicated (Beal et al. 2014; Ehrhardt et al. 2008). Finally, the fourth
239 factor is how genetic sequences nearby (or even further away within the genome) interact with the encoded device
240 and its function (Grigliatti and Mottus 2013; Laboulaye et al. 2018; Liu et al. 2015). Here, large-scale genomic
241 architecture, epigenetics, and proximal effects of being near other genes can all affect device behavior.

242 **Expression stability of synthetic genetic devices.** One of the most common techniques used for prototyping
243 genetic devices is transient transfection, the process of introducing non-integrating DNA or RNA into the cell (Kim
244 and Eberwine 2010). Being *transient*, the DNA or RNA is not replicated by the cell, and can be degraded by nucleases
245 and diluted out during cell division. This lack of temporal stability in the expression of the genetic device can impose
246 challenges for quantifying its steady-state behavior. Transfected DNA or RNA can be made stable through the inclu-
247 sion of sequences and protein factors in the cell that enable replication. For example, plasmid DNA becomes able to
248 self-replicate through the expression of the large T antigen from the SV40 virus and inclusion of the SV40 origin of
249 replication on the plasmid (Mahon 2011). RNA can self-replicate through expression of non-structural proteins from
250 alphaviruses and inclusion of genetic sequences from those viruses in the RNA (Wahlfors et al. 2000). An important
251 consideration for both of these technologies is that they can have profound effects on the cell's growth and development
252 (Ahuja et al. 2005; Beal et al. 2014), which can feed back onto the device itself and affect its performance through cel-
253 lular context (explored in detail in the next section). Given that they are not integrated into the genome, episomal DNA
254 and RNA experience limited interactions with other genetic sequences in the cell, which is advantageous for design.
255 Nevertheless, multiple genes or protein coding sequences delivered in one strand of RNA or DNA can still affect each
256 other's expression (Yeung et al. 2017; Wagner et al. 2018; Liu et al. 2017). While typically ignored, plasmid DNA
257 can interact with histones and thus form chromatin (Tong et al. 2006). Thus, more rapid epigenetic effects (Bintu et al.
258 2016) should not be ignored in transient transfections. Overall, episomal devices can be relatively isolated from the
259 cell's genetic context, but tend to degrade or dilute out after several cell divisions.

260 To ensure that the DNA on which a genetic device is encoded is stably maintained within a cell over time while
261 not depending on exogenous proteins, genomic integration is widely used. Genomic integration can be achieved
262 through directed DNA repair, recombination, transposition, or viral integration (Smith 2007; Nayerossadat et al. 2012;
263 Yamaguchi et al. 2011; Rutherford and Van Duyne 2014; Duportet et al. 2014), all of which affect the efficiency of
264 integration and ultimately the genetic context of the device. Genomic integration of synthetic devices can introduce
265 significant positional effects, where transcriptional activity in the local DNA environment, such as read-through from
266 upstream transcription (Loughran et al. 2014; Li and Zhang 2019), DNA torsional effects (Yeung et al. 2017; Sevier
267 and Levine 2018), DNA looping (Hao et al. 2019), and the activity of enhancers and silencers (Liu et al. 2015) interfere
268 with the prescribed function of the genetic device (**Figure 5C**). Transposons and viral integration strategies generally
269 lead to semi-random integration of exogenous genetic materials (Yant et al. 2005; Staunstrup et al. 2009; Vranckx
270 et al. 2016), with little to no control over the genetic position of the device in the mammalian cell genome. In an
271 effort to overcome positional effects, recent developments in genetic engineering technologies have enabled more
272 predictable control over integration sites of exogenous genetic material, including the landing pad DNA integration
273 platform (Duportet et al. 2014; Gaidukov et al. 2018) and targeted CRISPR-based approaches for insertion into "safe
274 harbor" loci, which experience reduced epigenetic silencing and ensure the device does not interfere with core cell
275 functions such as cell cycle regulation (Papapetrou and Schambach 2016). Thus, while delivery of genetic devices
276 via such random integration methods is often more efficient than targeted integration, the expression and regulation

277 of the devices will have a larger dependence on location of integration, as seen from bacterial studies (Segall-Shapiro
278 et al. 2018). Device performance will vary from cell to cell and among multiple integrated copies of a device per cell
279 (Jordan et al. 2001).

280 **Epigenetic modifications in the synthetic device locale.** Another critical facet of eukaryotic genetic context is
281 the local epigenetic state, including DNA methylation, histone tail modification, chromatin spreading and compaction,
282 and DNA coiling, all of which can interfere with gene expression and regulation, even to the point of gene silencing
283 (Allis et al. 2007; Allis and Jenuwein 2016; Yeung et al. 2017). Protection mechanisms against the local genetic
284 environment have been proposed in the form of insulator elements, which aim to decouple the activity of genes from
285 inappropriate transcriptional signals (West et al. 2002; Liu et al. 2015) or block epigenetic silencing (Müller-Kuller
286 et al. 2015). Despite these advancements, genetically integrated devices cannot be completely decoupled from their
287 local DNA context. To enable this decoupling, the creation of an artificial chromosome has been posited as a potential
288 carrier for embedded synthetic genetic devices (Lienert et al. 2014; Prochazka et al. 2017), though such a system has
289 not yet been developed. These advancements in genetic engineering technologies provide strategies to help overcome
290 perturbations from the genetic context by physically shielding the device from these anticipated effects.

291 **Copy number variability.** For both episomal and integrated genetic devices, a significant source of cell-to-cell
292 variability comes from differences in the copy number of genetic devices delivered per cell. For example, transient
293 transfection leads to large differences in plasmid delivery, with some cells receiving just one plasmid that then quickly
294 dilutes out, and other cells receiving upwards of a thousand plasmids (Bleris et al. 2011; Jones et al. 2020). This
295 variation comes from the method of preparing nucleic acids for delivery as well as from how cells receive them.
296 Though it can impose challenges, the variance in genetic device delivery by transfection also allows for the exploration
297 of device behavior at different copy number regimes and part stoichiometries using quantitative single cell analysis
298 pipelines (Gam et al. 2019). Thus, variance can be a source of both frustration as well as information about genetic
299 device design that should be minimized where needed and exploited where possible. For viral integrations, the copy
300 number of device integrations is determined by the multiplicity of infection (MOI), which represents the number of
301 infectious viral particles per cell during transduction. The distribution of copy numbers across cells can be well-
302 modeled with a Poisson distribution (Ailles et al. 2002; Prasad et al. 2011), where the coefficient of variation (standard
303 deviation divided by mean) decreases as a function of the MOI. Thus, high MOI infections can be used to ensure high
304 integration efficiency, reduce noise from copy number variation, and also reduce the relative impact on expression of
305 any one integration position. However, the use of high MOI transductions has the trade-off that high copy numbers of
306 the genetic device increases demand for limited cellular resources and can be expected to increase toxicity.

307 **The evolving DNA substrate.** The evolving nature of DNA also contributes to genetic context effects, where
308 random mutations to DNA-based devices can cause them to evolve over time and lose functionality (Liao et al. 2019)
309 or cause unexpected, environmental-dependent discrepancies in their behavior (González et al. 2015). Overall, activity
310 and change in the local genetic context imposes perturbations to the performance of the engineered genetic device.
311 These perturbations can then impact the temporal stability and predictability of the I/O response of a genetic device
312 while also creating cell-to-cell heterogeneity in device function. While such mutations may be useful for directed
313 evolution experiments, they can be detrimental to forward design and necessitate sophisticated strategies to maintain
314 circuit function (Liao et al. 2019).

315 **Cell fate programming and the dynamic genetic context.** Large-scale cell state changes that accompany move-
316 ments between cell types often involve the overexpression of TFs (Jopling et al. 2011), which drive heightened tran-
317 scriptional activity. This may increase the perturbations caused by genetic activity nearby the synthetic device, such

318 as read-through or physical torsional effects. As the cell undergoes fate transformation, the epigenetic state of the cell
319 will also change. Changes to the epigenetic landscape impact DNA accessibility, influencing the ability to target loci
320 for stable integration of synthetic devices into the genome. The epigenetic changes that accompany cell fate program-
321 ming may also result in silencing of genetic devices inserted into the genome in the starting cell state. Indeed, this
322 has been used as a hallmark of successful cell fate transition in the context of somatic cell reprogramming (Takahashi
323 and Yamanaka 2006), indicating that the final cell state is stabilized in a manner that is independent of exogenous TF
324 expression.

325 **Cellular context: hidden interactions with the regulatory hairball**

326 Synthetic genetic devices are situated within the cellular processor, whose state is shaped by molecular players
327 (DNA, RNA, and protein) that engage in dynamical regulatory interactions with one another in the cell, often de-
328 scribed as a hairball due to its highly interconnected nature (Yan et al. 2016) (**Figure 5A**). The complex nature of this
329 regulatory hairball makes it fertile ground for unexpected or "hidden" interactions among synthetic genetic devices
330 and the cellular processor. These hidden interactions are not specified by the device's design but rather originate from
331 uncontrolled and unmodeled mechanisms. Although there are myriad hidden interactions, here we focus on those that
332 can be grouped into one of the following two categories: *direct* interactions with the cell state and other devices and
333 *indirect* interactions with the cell state and other devices, where "other devices" can be both endogenous and synthetic.
334 The first group includes effects such as unknown cross-reactivity with molecular species within other devices or in the
335 cellular processor, direct ways in which the cell state affects the genetic device, and direct ways in which the genetic
336 device affects cell state. The second group includes issues of resource sharing, growth inhibition, and retroactivity.
337 In either case, they can be represented within a block diagram formalism as input disturbances to the genetic device,
338 which cause deviations from expected device behavior (**Figure 5B**).

339 **Direct interactions with the cell state and other devices.** In the human genome, there are tens of thousands of
340 genes encoding proteins and functional RNAs (Pertea et al. 2018). For many of these genes, there are numerous tran-
341 script variants that can be generated via different transcription start sites, alternative splicing, and RNA modifications
342 (Pertea et al. 2018; Grosjean 2005; Fisher and Beal 2018). In each different cell type, a unique combination of these
343 RNA variants are expressed, ultimately producing the protein and RNA regulators that define the given state of the
344 cell. These regulators affect the level of cellular resources that the genetic device uses as well as the state of the DNA
345 or RNA on which it is encoded. For example, changes in cell state often drive large-scale changes to chromatin, which
346 among other things affects the ability of TFs to accomplish their intended functions by limiting their access to DNA
347 (Cheedipudi et al. 2014). Thus, cell state changes can severely affect biochemical parameters describing transcription
348 and translation rates within the synthetic genetic devices. These devices can, in turn, also affect cell state by design,
349 such as through reprogramming cellular identity (Takahashi and Yamanaka 2016). In these cases, hidden interactions
350 can emerge between the device and the cell processor.

351 Genetic devices can further interfere with cell state through unwanted activation of the cell's innate immune re-
352 sponses (Kitaada et al. 2018). Many of the genetic devices used in mammalian cells are composed of DNA, RNA,
353 and proteins derived from non-human sources, such as bacteria and yeast. The use of bacterial proteins in mammalian
354 cells has been reported to elicit an immune response (Prochazka et al. 2017). To get around this problem, recent efforts
355 in synthetic biology have aimed to develop humanized genetic devices, composed of parts that are designed based on
356 bacterial counterparts without containing their components. For example, a recent report developed a CRISPR/Cas-

357 inspired RNA targeting system that allows for RNA editing, degradation, or translation (Rauch et al. 2020). Further
358 developments in this space can help to overcome interference from the innate cell response following synthetic device
359 operation.

360 A key property of synthetic genetic devices is that the intended input and output regulators are designed to be
361 orthogonal to the cellular processor and to other genetic devices. Orthogonality requires that (1) regulatory outputs
362 of a genetic device do not directly regulate endogenous genes unless specified by design, (2) genetic devices are not
363 regulated by endogenous genes unless specified in the design, and (3) regulatory outputs of one synthetic genetic
364 device are inputs only to a specified set of devices and not to others. Collectively, we refer to unexpected regulatory
365 interactions among synthetic and cellular genetic devices as "off-target" interactions, which challenge orthogonality
366 (**Figure 5B**). Off-target interactions can significantly affect genetic device function and the expression of natural genes
367 (Rowland et al. 2012; Singh et al. 2016; Meyer et al. 2019). Orthogonality is difficult to achieve within cells because
368 most molecular species have the chance to come in contact with each other throughout their lifetimes. Thus, much
369 work has gone into finding and engineering regulators that work orthogonally to one another and to the cell's processor
370 (Gaber et al. 2014; Stanton et al. 2014; Li et al. 2015; Weinberg et al. 2017; Cella et al. 2018; Gao et al. 2018; Gam
371 et al. 2019; Langan et al. 2019; DiAndreth et al. 2019; Chen et al. 2020; Donahue et al. 2020).

372 The eukaryotic cell context presents a further contextual challenge due to the non-homogeneous distribution of
373 cellular parts and resources in cellular compartments, often requiring shuttling of components for synthetic genetic
374 parts between the nucleus and cytoplasm. As a result, design of exogenously expressed parts needs to consider
375 additional requirements to ensure their correct spatial localization following expression (Alberts et al. 2014; Barajas
376 and Vecchio 2020). For example, nuclear localization signals and nuclear export signals are used to direct proteins
377 into and out of the nucleus, respectively. However, hidden interactions may interfere with mechanisms that regulate
378 spatial arrangement of parts, leading to their incorrect placement in the cell. A lack of spatial compartmentalization
379 within the nucleus and cytosol may also increase off-target interactions, allowing for gene regulators to interact with
380 DNA, RNA, and proteins indiscriminately, with the probability of interaction dependent on the strength of binding.

381 **Indirect interactions with the cell state and other devices.** Another way in which genetic devices affect cellular
382 state is by indirectly impacting the survival and growth dynamics of the cell, which in turn affects the dynamics of
383 the devices, creating another feedback loop that is challenging to analyze (**Figure 5B**). For example, overexpressing
384 genes that demand large amounts of the cell's resources can be detrimental to cell viability (Berger et al. 1992; Gilbert
385 et al. 1993; Baron et al. 1997; Lin et al. 2007). For cells that survive, selection against resource-demanding genetic
386 devices can cause changes to the cell processor or to the genetic device itself (González et al. 2015; Gouda et al. 2019).
387 Due to resource depletion, where the cell lacks sufficient resources for its housekeeping processes, resource loading
388 can reduce cellular growth rates, which has been observed in both bacterial (Ceroni et al. 2015) and mammalian cells
389 (Jones et al. 2020). Cell cycle has been shown to drive transcriptional noise and stochasticity (Zopf et al. 2013) and
390 more recently cell cycle length has been suggested as a mechanism to control the transcription of genes based on their
391 sequence length (Chakra et al. 2020). As a consequence, any perturbations to cell proliferation dynamics will also
392 indirectly affect transcriptional regulation. At a more global level, molecule dilution due to cell division impacts the
393 decay rate of all molecules, which dictate key temporal dynamics of genetic devices (Del Vecchio and Murray 2014).
394 Hence, genetic device-induced growth rate changes globally influence the function of both cellular and synthetic
395 genetic devices, causing a feedback loop that is very difficult to untangle (**Figure 5B**).

396 Indirect interactions also arise due to problems such as competition for shared factors in the cell. One such
397 way that this manifests is through competition for broadly-shared gene expression resources (which has been noted

398 in both mammalian and bacterial cells), such as transcriptional machinery (Courey 2008; Jones et al. 2020), post-
399 transcriptional processing factors (Grimm et al. 2006; Castanotto et al. 2007; Boudreau et al. 2009; Munding et al.
400 2013), translational machinery (Gyorgy et al. 2015; Frei et al. 2020a), and factors affecting protein stability (Lobanova
401 et al. 2013). Individual genes and proteins can also compete for shared regulatory inputs, such as gRNAs competing
402 for shared pools of dCas9 to regulate target promoters (Fontana et al. 2018; Zhang and Voigt 2018). Even with a
403 well-designed genetic device that operates orthogonally to the cell processor and uses individual components that are
404 themselves orthogonal to one another, resource competition can induce unintended changes in gene expression and
405 disrupt the function of genetic devices and circuits (Del Vecchio 2015; Qian et al. 2017; Sabi and Tuller 2019; Jones
406 et al. 2020; Frei et al. 2020a).

407 In most cases, resource loading by one gene reduces the expression level of all other genes through the sequestra-
408 tion of factors needed for transcription and translation. In bacteria, the most limiting resource is the ribosome, with
409 RNA polymerase also being important (Gyorgy et al. 2015). In mammalian cells, transcriptional resources appear to
410 be most limiting (Jones et al. 2020), though RNA-level effects have been observed in several cases (Munding et al.
411 2013; Frei et al. 2020a). However, production resources are not the only factors that genes can compete for. As with
412 changes in cell growth rate, competition for RNA or protein degradation machinery can influence gene expression dy-
413 namics, thereby altering genetic device behavior (McBride and Vecchio 2017; Cookson et al. 2011). A special case of
414 resource competition comes from competition among genes (potentially both synthetic and natural) for a shared gene
415 regulator. Specifically, when a TF binds to target DNA, the temporal dynamics of the free TF concentration changes
416 and leads to significant alterations in the behavior of genetic devices regulated by it. This phenomenon is referred
417 to as retroactivity (Del Vecchio et al. 2008), and is typified by the addition of downstream genetic devices disrupting
418 the behavior of upstream modules. Retroactivity is caused by the sequestration (loading) of an output molecule by
419 multiple downstream targets. This can cause effects ranging from changing the bias of bistable switches to going so
420 far as to destroy sensitive temporal behaviors such as oscillations (Del Vecchio et al. 2008; Jayanthi et al. 2013; Lyons
421 et al. 2014; Mishra et al. 2014; Pantoja-Hernández and Martínez-García 2015; Menon and Krishnan 2016). Inevitably,
422 genetic devices that share the same regulatory inputs become indirectly coupled together through resource loading
423 while genetic devices with multiple outputs experience retroactivity.

424 All of the above described interactions lead to disturbance inputs to the genetic device (**Figure 5B**). Since un-
425 accounted for and largely unknown, these disturbances dramatically reduce device predictability in the mammalian
426 context. Many off-target interactions are expected to result from our incomplete understanding of the physical prop-
427 erties of the molecular players that compose the cellular processor, as well as of the reactivity between them (Zechner
428 et al. 2020). To this end, emerging synthetic biology tools can help to elucidate the regulatory hairball (explored in a
429 later section).

430 **Cell fate programming and the dynamic cell state.** The dynamic nature of the transcriptional and epigenetic
431 environment during cell fate conversion imposes the additional complexity of time-varying context effects. As such,
432 the degree and nature of perturbations to the synthetic device's performance can be expected to be dynamic in nature.
433 In fact, epigenetic changes that allow cells to exit their identity and stabilize as a new cell type during cell fate
434 programming may result in the silencing of genes that were relevant and accessible in the starting cell state but not in
435 the new attained state (Plath and Lowry 2011; Teshigawara et al. 2017). Further, genetic devices that affect cell state
436 will directly alter cellular context itself. Competition for resources, undesirable interactions among genes, burdens
437 imposed on cell growth, and alterations in cell-cell signaling may all vary depending on the state or type of the cell.
438 Just as the changing cell state impact device function, so too do synthetic devices have unintentional impacts on cell

439 state, particularly in cell fate applications. Indeed, it is understood that the derivation of PSCs through reprogramming,
440 as well as their culture *in vitro* can result in mutations and genetic/epigenetic abnormalities (Hussein et al. 2011; Lund
441 et al. 2012; D'Antonio et al. 2018; Merkle et al. 2017).

442 **Extracellular context: niche interactions and population effects**

443 Mammalian cells naturally live in multicellular societies, where they are regularly engaging in interactions with
444 neighboring cells and receiving microenvironmental cues. Since the state of the cellular processor is shaped by mi-
445 croenvironmental signals, the behavior of a synthetic genetic device that is transplanted into the endogenous context is
446 inevitably also influenced by signals from the cellular niche. The impact of microenvironmental cues on the changing
447 cell state thus indirectly affects synthetic devices (**Figure 5B**).

448 The microenvironmental context also offers challenges for properly testing and characterizing synthetic genetic
449 devices. In particular, there is a growing awareness that multicellular populations are not a sum of their parts and
450 thus careful quantification of underlying single cell dynamics is required when measuring the function of synthetic
451 devices. Just as the microenvironmental context can impact the behavior of synthetic circuits, so too can synthetic
452 devices drive changes to the growth and death dynamics of multicellular populations. This is increasingly relevant
453 for mammalian cell system, where cell-cell killing has recently been uncovered, driven by the differential expression
454 of key "fitness" genes, such as Myc (Clavería et al. 2013; Sancho et al. 2013; Dejosez et al. 2013; Díaz-Díaz et al.
455 2017). Thus, if synthetic devices perturb the genetic fitness landscape of the cell – perhaps through direct or indirect
456 regulation of fitness genes – they may drive the selection of a subset of cells. By impacting cell fitness, synthetic
457 devices can also drive changes to a cell's proliferation rate and metabolic profile (Lawlor et al. 2019), thus driving
458 changes to cell state. In turn, the synthetic devices can then drive the clonal dynamics of the multicellular population
459 and lead to unanticipated consequences.

460 The impact of genetic manipulations on mammalian cell survival dynamics have not yet been thoroughly explored.
461 In fact, the insertion site of the device itself in the genome has been shown to influence the growth dynamics of the
462 engineered cells, possibly interfering with the function of oncogenes and leading to preferential growth of a subset
463 of clones (Maldarelli et al. 2014; Wagner et al. 2014). There is growing evidence of this in the context of CAR-T
464 cells, where lentiviral insertion site of the exogenous CAR has been shown to impact the preferential survival and
465 dominance of a subset of clones (Shah et al. 2019; Nobles et al. 2019) and specific knock-in to the *TRAC* locus can
466 improve anti-tumor therapy (Eyquem et al. 2017). The relationship between integration site and clonal dominance
467 has also been reported in the context of retrovirus-mediated gene therapy (Hacein-Bey-Abina et al. 2003). Lentiviral
468 integration has also been reported to induce changes in alternative splicing patterns and lead to aberrant transcripts
469 (Moiani et al. 2012), while also causing insertional mutagenesis (Bokhoven et al. 2009). Thus, the synthetic device
470 and endogenous regulatory network of the cell influence each other's states and introduce perturbation, both intentional
471 and accidental. By influencing clonal dynamics, synthetic devices can thus shape the multicellular context and bias
472 experimental measures of their own performance.

473 **Cell fate programming and the evolving multicellular society.** An additional layer of complexity for cell fate
474 programming applications arises from the dynamic nature of multicellular populations, particularly PSCs and their
475 derivatives. Initiatives in regenerative medicine to direct differentiation and reconstruct functional tissues yield sys-
476 tems with complex cell-cell and cell-niche interactions that can be difficult to model and can affect genetic device

477 function. Cell division is a common occurrence in cell fate programming applications, including reprogramming
478 and differentiation to specialized cell types. Individual cells undergoing fate programming can expect to give rise to
479 progeny through the process, which introduces extracellular context effects. Indeed, the mammalian cell biology and
480 stem cell fields have recently recognized that seemingly homogeneous populations of cells engage in active compe-
481 tition with one another, leading "fitter" cells to eliminate their seemingly weaker neighbors (Shakiba and Zandstra
482 2017; Baker 2020). This observation has gained particular attention in PSC populations, where mouse PSC have been
483 shown to engage in active elimination of one another both *in vitro* (Sancho et al. 2013; Díaz-Díaz et al. 2017) as well
484 as during embryonic development (Hashimoto and Sasaki 2019; Clavería et al. 2013; Dejosez et al. 2013). Through
485 interactions with neighbors, cell competition drives changes to the individual cell's state, triggering proliferation or
486 death, as well as stem cell differentiation or extrusion. In fact, competitive interactions have been shown to drive the
487 dynamics of cell populations during cell fate programming, where an elite subpopulation of cells that is primed to
488 undertake the fate transition is selected for and dominates the cell population (Shakiba et al. 2019).

489 In addition to elite cell subpopulations that overtake multicellular populations undergoing fate transitions, neutral
490 selection also plays a role in driving the growth dynamics of stem cell populations, where some clones overtake the
491 cell population simply by chance. Indeed, neutral drift has been shown to play a role in tissue homeostasis *in vivo* and
492 can be expected to impact *in vitro* systems as well (Krieger and Simons 2015). The local microenvironmental context
493 of cells undergoing cell fate programming is therefore dynamic and the nature of perturbations to the synthetic device's
494 performance will be dependent on the cues received from neighboring cells. Similarly, cell therapies that are geneti-
495 cally engineered to carry synthetic devices, such as CAR-T cells, will also face changes to their microenvironment as
496 they are transitioned to *in vivo* environments in patients, bringing on substantial unknowns in terms of extracellular
497 context. Clearly, cell fate programming applications that aim to guide the movement of cells on the Waddington land-
498 scape cannot ignore the effect of multicellularity and the extracellular context in influencing the cell's trajectory, and
499 thus the ability to predictably control this (**Figure 1A**).

500 **Synthetic biology tools for resolving context dependency**

501 Through the development and application of technologies for tracking the intra- and extra-cellular context, syn-
502 thetic biology tools have facilitated efforts to reverse engineer the structure and function of the cell's processor as
503 well as its interfacing inputs (Lienert et al. 2014; Mathur et al. 2017). For example, the development of libraries to
504 tune endogenous gene expression (Jost et al. 2020) can provide new insights into the dose-dependent role of genes in
505 driving cell fate decisions, as well as the regulatory interactions between genes.

506 Analogously, DNA-based devices for lineage tracking are powerful tools for understanding how our synthetic ge-
507 netic circuits influence cell state, as well as how growth and death dynamics influence our interpretations of circuit
508 function during testing (Shakiba et al. 2019; Gerrits et al. 2010). Clonal tracking using DNA barcoding (Kebschull
509 and Zador 2018) has revealed that the growth and death dynamics of the clones that compose multicellular mammalian
510 population may differ greatly, thus leading a subset of the clones to drive the dynamics of the overall population (Shak-
511 iba et al. 2019). This is an important consideration when interpreting experimental data during testing of synthetic
512 device performance in cells, where population-averaged measurements may not provide an accurate picture of the
513 device performance in individual cells. This is particularly the case if neutral or elite clonal dynamics in the culture
514 give rise to a subset of dominant clones overtaking the population. Lineage tracking strategies are also powerful tools
515 for understand whether the presence of a synthetic device influences cell fitness, which leads to the elimination or

516 selective propagation of a subset of cells in culture. By comparing the clonal dynamics of engineered cells that carry
517 our synthetic circuits with wild-type cells that do not, we can assess the impact of the synthetic device on cell survival,
518 proliferation, and cell-cell interactions.

519 When coupled with temporal single cell gene expression analysis, lineage information can be used to better un-
520 derstand the trajectory of cell state changes of individual cells (Weinreb et al. 2020). Recent advancements in genetic
521 engineering technologies, with the discovery of CRISPR/Cas gene editing tools (Mali et al. 2013; Cong et al. 2013),
522 has also enabled the development of DNA-based event recorder technologies, such as: mSCRIBE, in which two self-
523 targeting gRNAs are used to record activity of the NF- κ B inflammation pathway in mouse cells (Perli et al. 2016);
524 CAMERA, which can record temporal Wnt activity of human cells in a cell-embedded DNA tape (Tang and Liu 2018);
525 DOMINO, which also records order information of environmental stimuli (Farzadfard et al. 2019); TRACE, which
526 allows simultaneous recording of multiple temporal stimuli in bacteria (Sheth et al. 2017); and SENECA, which en-
527 ables transcriptome-scale molecular recording in bacteria (Schmidt et al. 2018). DNA-based recording devices like
528 these open the door to unraveling the cellular hairball by allowing for temporal tracking of molecular species (such as
529 mRNAs) within the cell's regulatory networks.

530 These expanding synthetic biology toolsets have catalyzed efforts to reverse engineer the cellular processor and its
531 inputs. Undoubtedly, a more complete understanding of the cellular system will help to better anticipate perturbations
532 to genetic device performance, allowing for synthetic genetic circuit designs to be well-informed of cellular and
533 extracellular context effects. Nevertheless, the lingering unknowns of the mammalian cell context, as well as the
534 stochastic features of the cellular processor, continue to challenge robust and predictable synthetic circuit design.

535 **Context-aware device design**

536 Context-dependent effects across the genetic, cellular, and multicellular scales serve as perturbations to synthetic
537 devices that seek to regulate gene expression. This necessitates the development of genetic devices that can correctly
538 parse inputs to outputs and drive cellular behavior regardless of context. We refer to these classes of devices as
539 "context-aware", as their design accounts for the physical sources of context effects. Though there are many sources
540 of context-dependence, we can abstract their effects on a given genetic device by considering the effect of the contex-
541 tual factors on basic gene expression processes: transcription, post-transcription (*i.e.*, mRNA decay or modification),
542 translation, and post-translation (*i.e.*, protein decay or modification). This framework simplifies the view of context
543 in a way that also conveniently aligns with the conception of modular genetic devices as elements in which we can
544 modulate one or more of these rates (**Figure 3**). Thus, to build devices that are robust to specific context factors, it
545 is necessary to desensitize the devices to either the factors themselves or to the parameters that are affected by such
546 factors. A primary method to approach this problem is through the design of genetic controllers that, through their
547 topology and operating regimes, desensitize genetic device output to certain parameters that are affected by distur-
548 bance inputs. Indeed, robust systems have been built through model-driven design that considers the effect of context
549 factors on system function. Here, we discuss genetic controllers and how they can be applied to insulate genetic device
550 function from context.

551 Basic principles of genetic controllers

552 A controller is a module that is connected to and regulates the behavior of a system, typically to enforce a desired
553 output despite perturbations (disturbances). Controllers can generally work via *feedforward* or *feedback* actuation
554 (**Figure 6A**). In natural regulatory networks, both feedforward and feedback control motifs have been observed to
555 impart high robustness and adaptation to disturbances (Barkai and Leibler 1997; Becskel and Serrano 2000; Yi et al.
556 2000; Ma et al. 2009; Sturm et al. 2010; Ferrell 2016; Araujo and Liotta 2018; Nunns and Goentoro 2018). A feedback
557 controller measures the system’s output, compares it to a desired output, and actuates an input to the system to decrease
558 the measured discrepancy between the desired and actual output. By contrast, a feedforward controller directly senses
559 disturbances and actuates an input to the system to compensate for the expected effect of these disturbances on the
560 output. To implement effective feedforward control, it is thus necessary to have a sufficiently descriptive model of
561 how the disturbance affects the output. Feedback controllers do not have such a requirement; however, they must be
562 carefully designed to ensure that the closed loop system is stable (Åström and Murray 2008).

563 To enforce a desired output regardless of disturbances, controllers work by minimizing the effect of such distur-
564 bances on the output (Del Vecchio and Murray 2014; Del Vecchio et al. 2016). In the simplest and most common
565 use-case, biological controllers can be used to enforce a constant level of a protein of interest. Specifically, we will say
566 that the controller achieves robustness (adaptation) to a given disturbance if, upon presentation of such a disturbance,
567 the level of the protein is able to reach, after some time, a value close to the pre-disturbance value. If the residual error
568 is exactly zero, the controller is said to achieve perfect adaptation to the disturbance (**Figure 6B**) (Del Vecchio and
569 Murray 2014). Perfect adaptation is possible with both feedforward and feedback controllers (Ma et al. 2009; Araujo
570 and Liotta 2018). In what follows, we review basic feedback and feedforward control design principles to achieve
571 high robustness and provide examples of how these have been implemented in either prokaryotic or eukaryotic cells.

572 **Feedback controllers for robustness.** At a high level, feedback controllers that regulate the level of a protein of
573 interest work by measuring the difference between the actual and target concentration (*i.e.* the error) of the protein,
574 then increasing or decreasing the production or decay rates of the protein as needed. A common and relatively simple
575 way to achieve robustness to some disturbance is the use of proportional, high-gain, negative feedback (Del Vecchio
576 and Murray 2014; Åström and Murray 2008), in which the degree to which protein production rate is adjusted is
577 proportional to the error. For the sake of illustration, the concept of high-gain feedback can be explained by the
578 following simple differential equation describing the rate of change of the level X of a protein of interest:

$$\frac{dX}{dt} = G(u - X) + d - \gamma X,$$

579 in which d represents a disturbance in the protein’s production rate and γ is the protein decay rate constant. Here, u
580 can be regarded as a desired protein level (*i.e.* *set point*) and $G(u - X)$ represents the control action with gain G , which
581 is proportional to the error between desired and actual protein level. The controller action increases production of the
582 protein of interest if $X < u$ and decreases it if $X > u$, thereby compensating the effect of d . In particular, at steady
583 state, if $G \gg \gamma$, the error (e) due to the disturbance is given by:

$$e = |u - X| \approx d/G,$$

584 which can be made arbitrarily small as G is increased, hence the name as “high-gain” feedback. More sophisticated
585 and non-linear variations of high-gain feedback are possible and have been used to design insulation devices and load

586 drivers in both bacterial and eukaryotic cells to insulate a TF output from loads applied by its downstream targets and
 587 non-specific DNA binding (Jayanthi and Del Vecchio 2011; Nilgiriwala et al. 2015; Mishra et al. 2014). Specifically,
 588 the eukaryotic load driver implementation (Mishra et al. 2014) uses post-translational protein modification, *i.e.*, phos-
 589 phorylation and dephosphorylation, in order to create a high-gain post-translational feedback controller that achieves
 590 adaptation to the presence and amounts of the output protein DNA binding targets.

591 High-gain feedback allows for increased robustness as the controller gain increases, but cannot achieve exactly
 592 zero error at steady state. Zero steady state error, and hence perfect adaptation, is reachable by the use of integral
 593 feedback (Åström and Murray 2008; Del Vecchio and Murray 2014) (**Box 1, Figure 7**). To implement integral
 594 feedback, a controller species (Z) is introduced such that its concentration acts as a molecular "memory" variable,
 595 where accumulation of Z implies a deviation of the protein of interest from target expression levels. Specifically, the
 596 resulting control action z is proportional to the integral of the error:

$$e = (u - X), \quad z = k \int_0^t e(\tau) \cdot d\tau,$$

597 in which $k > 0$ is a control gain, which modulates both the absolute degree of discrepancy between achieved and
 598 desired protein levels as well as the temporal persistence of this discrepancy.

599 The simplest mathematical model of this control strategy can be captured by the following two differential equa-
 600 tions:

$$\frac{dX}{dt} = Z + d - \gamma X, \quad \frac{dZ}{dt} = k(u - X),$$

601 in which the production rate of X is "actuated" by the concentration of the "memory" molecule Z . If u and d are both
 602 constant with time, the system achieves steady state (*i.e.*, the rate of change of the concentrations practically reaches
 603 zero), when $X = u$, which is completely independent of the disturbance d . The memory of past error, accumulated in
 604 the concentration of Z , critically enables an integral controller to eliminate steady-state error and thus achieve perfect
 605 adaptation. While feedback controllers require an integrator to achieve perfect adaptation, feedforward controllers can
 606 do so without explicitly creating an integrator (Mangan and Alon 2003; Del Vecchio et al. 2016), although it can be
 607 shown that a "hidden" integrator is present in their structure (Shoval et al. 2011).

608 Feedback controllers can, in principle, achieve robustness to those perturbations that affect the genetic device
 609 *within or upstream*, but not downstream, of the feedback loop created by the controller (**Figure 6C**). A significant
 610 benefit of feedback control over feedforward control is the ability to achieve robustness to uncertainty affecting the
 611 controlled system itself. This uncertainty can include uncertain parameters, noise, and unmodeled dynamics (Åström
 612 and Murray 2008; Del Vecchio and Murray 2014).

613 An important consideration in feedback controller design is the way in which the set point u enters the controller.
 614 If this way is itself affected by a disturbance d , the controller may not be able to adapt to d . For example, the
 615 bacterial antithetic small RNA (sRNA) feedback controller, which senses an output TF (X) and then produces an
 616 sRNA molecule to sequester and degrade the TF's mRNA transcript (Huang et al. 2018), can achieve almost perfect
 617 adaptation to disturbances affecting the translation of the output protein, such as from changes in the availability of
 618 ribosomes. However, because the input u is a transcription rate, this design cannot desensitize the output to changes
 619 in TX resources without also desensitizing the response to u . To avoid the latter problem, the design employed an
 620 amplification of the transcription rate by promoter tuning, which ensures the system output responds to u , but also
 621 sensitizes it to transcriptional perturbations. Similar problems can appear in other feedback controllers, so the model

622 should always be examined in detail to ensure that the critical parameters to which robustness are needed do not feed
623 into u .

624 **Feedforward controllers for robustness.** Feedforward controllers are commonly constituted by a molecular
625 species that offsets the effects of disturbances on the output of a regulated device. This is achieved by sensing such
626 disturbances in a manner that is equivalent to how they affect the device output, then eliciting a proportional negative
627 regulation of the device's output. At a high level, feedforward controllers can be implemented by either enhancing
628 the decay rate or by inhibiting the production rate of the target molecular species in the genetic device, typically the
629 mRNA or protein species (Del Vecchio and Murray 2014; Shoval et al. 2011). The simplest differential equation model
630 describing the first mechanisms is given by

$$\frac{dX}{dt} = udK - ZX - \gamma X, \quad \frac{dZ}{dt} = dK - Z,$$

631 in which d can be regarded as a perturbation of transcription rate, such as due to varying DNA copy number or
632 to variable transcriptional resources, which affects both the device and controller in the same way. Indeed, if K is
633 sufficiently large, we obtain that at steady state $X \approx u$, independent of the disturbance d , reaching almost perfect
634 adaptation. Implementations of this principle have appeared in mammalian cells in order to make the expression level
635 of a protein robust to variation in DNA copy number (Bleris et al. 2011; Jones et al. 2020) or to resource loading
636 (Jones et al. 2020; Frei et al. 2020a). In both cases, the feedforward actuation enhances the decay rate of the output
637 protein's mRNA, via either a miRNA (Bleris et al. 2011; Frei et al. 2020a) or an endoribonuclease (Jones et al. 2020).

638 A simple model of a feedforward controller implemented by inhibition of production rate of the output protein is
639 given by

$$\frac{dX}{dt} = \frac{ud}{1+Z} - \gamma X, \quad \frac{dZ}{dt} = dK - Z,$$

640 in which if K is sufficiently large, for non-zero d , we obtain that at steady state $X \approx u$, independent of the disturbance d ,
641 thereby also reaching almost perfect adaptation. This mechanism was implemented in both bacterial (Segall-Shapiro
642 et al. 2018) and mammalian (Bleris et al. 2011) cells to obtain adaptation of protein expression levels to variation in
643 plasmid copy number. In this design, Z is a transcriptional repressor of X expressed from the same plasmid as X in a
644 manner that ensures the same disturbance d affects both the device and the controller proportionally. The requirement
645 for Z to repress the production of X without cooperativity (*i.e.*, with power 1 in the equation) has made it difficult to
646 implement feedforward control with transcriptional regulators (Bleris et al. 2011; Segall-Shapiro et al. 2018), which
647 frequently bind to DNA in a cooperative manner (Zhang et al. 2013).

648 A feedforward controller can impart robustness to disturbances that the controller can sense (**Figure 6D**). Com-
649 pared to feedback controllers, feedforward controllers have a reduced risk for instability. However, unlike feedback
650 controlled systems, feedforward-controlled systems are, in general, not robust to parameter variability within either
651 the controller or controlled system.

652 **Limitations to controller implementations in biological systems**

653 Well-designed controllers can, in principle, allow perfect adaptation to disturbances; however, there are challenges
654 for implementation in living cells. One major hurdle is the decay (γ) of controller species via degradation and dilution,

655 which for integral feedback controllers creates a leakiness in the integrator function:

$$\frac{dZ}{dt} = k(u - X) - \gamma Z,$$

656 This decay can arbitrarily worsen the adaptation performance. Performance can be rescued by ensuring that the
657 controller reactions implementing the integrator are sufficiently faster than molecule decay, effectively making the
658 decay term negligible, leading to “quasi-integral” control (Qian and Del Vecchio 2018) (see **Box 1**).

659 While integral feedback control can guarantee adaptation to constant disturbances, real perturbations are often
660 time-varying. In this case, proving disturbance rejection is substantially more challenging but it is possible under
661 suitable assumptions for time-varying disturbances that operate on a slower timescale than the controller reactions
662 (Qian and Del Vecchio 2019). There are also tradeoffs between the rate of convergence to steady-state and the resulting
663 steady-state error of the output relative to the set point (Olsman et al. 2019).

664 A common limitation in the implementation of feedback controllers is that the sensor of the output species X or
665 M is not necessarily the actual output protein or RNA, and thus is only a proxy for the true output Y . If X and Y are
666 both proteins, such a proxy can be obtained in mammalian cells by 2A-linking (Szymczak et al. 2004) X and Y or
667 using an IRES (Hellen and Sarnow 2001) to separate their coding sequences, both of which ensure that X and Y are
668 translated into separate peptides from the same RNA species. In bacteria, this can be done more simply by placing
669 both coding sequences within an operon (Qian and Del Vecchio 2018; Aoki et al. 2019). Co-transcription without
670 co-translation may cause the levels of the two proteins to become decoupled and respond differently to disturbances,
671 therefore hampering the controller performance. This can be ameliorated by fusing X and Y , though the feasibility of
672 doing so is confounded by the potential for fusion to disrupt the functions of X and/or Y . Additionally, fusions are not
673 useful when the species must occupy different compartments inside or outside of the cell.

674 Feedforward controller implementations also have important limitations. Since feedforward controllers require
675 separation between the control and output branches, they do not provide any robustness to disturbances that dispro-
676 portionately affect one branch over the other. For example, if any off-target interactions affect the output branch but
677 not the control branch, then the control branch will not be able to compensate. Thus, feedforward controllers must
678 be carefully designed, down to the sequence level, to capture as many relevant disturbances as possible. They are
679 also generally quite vulnerable to changes in the relative decay rates of X and Z , which can cause the feedforward
680 mechanism to over- or under-compensate, depending on the parameter regimes (Jones et al. 2020). This can occur if,
681 for example, the degradation rates of X and Z are different, and the cell growth rate changes.

682 Finally, while the development of controllers for use in bacteria has advanced rapidly in the past decade, such de-
683 velopment is lagging behind in mammalian cells. This can partially be explained by the greater intensity and longevity
684 of research in bacterial synthetic biology compared to mammalian synthetic biology, as well as by the lengthier de-
685 sign cycles inherent in engineering mammalian cells. Thus, as we aim to build control systems for applications in
686 regenerative medicine, cell therapy, programmed organoids, and other areas of mammalian synthetic biology, there
687 will continue to be a need to port solutions from bacteria to mammalian cells and to realize new mammalian designs
688 that can remedy the numerous unique context-dependencies found in mammalian systems.

Applications of controllers to insulate genetic device function from context

Over the past several years, a number of synthetic genetic controllers have been developed for bacterial, yeast, and mammalian genetic devices to achieve robustness to various context-dependencies. A summary of different controllers, the organisms they were built for, and the context-dependencies solved are presented in **Table 2**. Schematics for the enzymatic feedback, antithetic feedback, and feedforward designs are provided in **Figure 9A, B, and C**, respectively.

Controller architecture	X	Z	Robust output rates	Implementations
Enzymatic feedback	Phosphatase	TF	$\alpha^{**}, \delta^{**}, \beta^*, \gamma^\dagger$	Bacteria (Chang et al. 2013), Mammalian (Jones et al. 2021)
	miRNA	RBP	$\alpha^{**}, \delta^*, \beta^*, \gamma$	Mammalian (Bloom et al. 2015)
	miRNA Degron unlocker	TF TF	$\alpha^{**}, \delta^\dagger$ $\alpha^*, \delta^*, \beta^*, \gamma^\dagger$	Mammalian (Lillacci et al. 2018) Yeast (Ng et al. 2019)
Antithetic feedback	TF	Scaffold/anti-scaffold	$\alpha, \delta, \beta, \gamma^\dagger$	Bacteria (Hsiao et al. 2015)
	Sigma factor	sRNA/RNA	$\alpha^\dagger, \delta, \beta, \gamma^\dagger$	Bacteria (Huang et al. 2018)
	TF	Sigma/anti-sigma factors	$\alpha, \delta, \beta, \gamma^\dagger$	Bacteria (Aoki et al. 2019)
	TF	mRNA/antisense RNA	$\alpha, \delta, \beta, \gamma^\dagger$	Mammalian (Frei et al. 2020b)
Proportional feedback	TF	(Same as X)	$\alpha^{**}, \delta^*, \beta^{**}, \gamma^\dagger$	Mammalian (Bleris et al. 2011), Bacteria (Shopera et al. 2017)
	RBP	(Same as X)	$\alpha^{**}, \delta^*, \beta^*, \gamma^\dagger$	Mammalian (Stapleton et al. 2012)
Feedforward	DNA	TF	$\alpha^\dagger, \delta^\dagger, \beta^\dagger, \gamma^\dagger$	Mammalian (Bleris et al. 2011), Bacteria (Segall-Shapiro et al. 2018)
	RNA	miRNA	α, δ^\dagger	Mammalian (Bleris et al. 2011), (Strovas et al. 2014; Frei et al. 2020a)
	Protein	Protease	$\alpha^\dagger, \delta^\dagger, \beta^\dagger, \gamma^\dagger$	Mammalian (Gao et al. 2018)
	RNA	endoRNase	$\alpha^\dagger, \delta^\dagger, \beta^\dagger, \gamma^\dagger$	Mammalian (Jones et al. 2020)

Table 2: Controllers to solve context-dependence. *Not measured. **Imperfect adaptation observed. \dagger Perfect adaptation conditional on relative parameters for controller and output species.

Robustness to DNA copy number variation. Feedforward controllers built with miRNAs, TFs, or endoRNases have been used to make gene expression robust to DNA copy number variation (Bleris et al. 2011; Lillacci et al. 2018; Segall-Shapiro et al. 2018; Jones et al. 2020) (Figure 9C-i, -ii, -iv), a key component of the overall transcription rate of a gene (α). These designs all operate by expressing the controller species from the same DNA strand as that of the genetic device. While different cells may have different copy numbers of the DNA, the expression of the controller species (miRNA (Bleris et al. 2011; Lillacci et al. 2018), TF (Bleris et al. 2011; Segall-Shapiro et al. 2018), or endoRNase (Jones et al. 2020)) and output protein are both proportional to the DNA copy number. Thus, as long as the controller species concentration linearly actuates decay of or inverse-proportionally actuates production of the output protein, changes in the transcription rate of the genetic device output are offset such that the output level is maintained across large ranges of DNA copy number.

Desensitizing gene expression to DNA copy number will be useful for stem cell engineering and regenerative medicine applications by enabling targeted overexpression of key gene regulators, allowing for precise programming of cell fate decisions. Currently, cell fate programming is typically achieved by overexpressing lineage-specific TFs with lentiviral- or transposon-based gene delivery systems (Takahashi and Yamanaka 2016), which can integrate a range of DNA copy numbers per cell. Precise gene expression control can be used to accelerate efforts to model diseases connected to exact gene expression levels (*e.g.* (Zhu et al. 2019)) by limiting copy number variation among cells, such that CRISPR or other targeted integration strategies are not needed.

711 **Robustness to resource loading.** More recently, both feedforward and feedback controllers have made gene
712 expression robust to changes in cellular resource availability (Shopera et al. 2017; Darlington et al. 2018; Huang et al.
713 2018; Frei et al. 2020a; Jones et al. 2020; Jones et al. 2021). In bacterial cells, feedback control has been used to
714 attenuate the effects of resource loading, *e.g.* from competition for ribosomes, on the level of protein produced by
715 genetic devices (Shopera et al. 2017; Darlington et al. 2018; Huang et al. 2018). In these designs, either transcriptional
716 or post-transcriptional control is applied to dynamically adjust protein production in response to resource fluctuations.
717 In particular, the mechanism of (Huang et al. 2018) is a quasi-integral antithetic feedback controller, in which the
718 controller reactions are made very fast in order to overcome integrator leakiness and reach almost perfect adaptation
719 to resource loading (Figure 9B-ii). While sRNA are bacteria-specific, an analogous system built in mammalian cells
720 that has antisense RNA in place of sRNA was shown to impart rejection to various disturbances, though resource
721 competition was not tested (Frei et al. 2020b) (Figure 9B-iv). In mammalian cells, feedforward control has been
722 implemented to robustly set protein expression levels in the face of transcriptional resource fluctuations. In these
723 designs, either a miRNA (Frei et al. 2020a) or an endoRNase (Jones et al. 2020) is used to sense changes in resource
724 availability and then offset the resulting changes in output production (Figure 9C-ii, -iv), similarly to how feedforward
725 control had previously been used to offset changes in DNA copy number (Bleris et al. 2011; Segall-Shapiro et al. 2018).
726 More recently, feedback control has also shown to reduce sensitivity of gene expression to resource loading and off-
727 target regulation at the transcriptional and post-transcriptional levels in mammalian cells (Jones et al. 2021) (Figure
728 9A-i)

729 At an abstract level, differences in the expression level of any given gene among different cell types is the result
730 of the differential expression levels of gene regulators in each cell type. Thus, to establish control over RNA and
731 protein expression that is robust to changes in cell state throughout processes such as reprogramming, differentiation,
732 and integration into complex environments such as tumors, it will be necessary to ensure engineered genetic circuits
733 can operate across diverse intracellular conditions. Early evidence for controllers enabling such behavior has been
734 observed with the endoRNase feedforward controller, with which expression levels across several cell lines were
735 precisely aligned (Jones et al. 2020).

736 **Robustness to noise via linearization of the transfer curve.** In natural biological circuits, linear amplification is
737 observed for many signaling networks (Nunns and Goentoro 2018). For example, the ERK MAPK pathway resembles
738 an enzymatic feedback controller: Raf phosphorylates and activates MEK, which phosphorylates and activates ERK,
739 which then feeds back by phosphorylating and deactivating Raf (Sturm et al. 2010). This feedback linearizes the
740 response from Raf activation to ERK activation (Sturm et al. 2010). In synthetic circuits, this principle has been applied
741 to make inducible genetic devices respond to their inducer inputs in a graded, uniform manner (Dublanche et al. 2006;
742 Nevozhay et al. 2009; Nevozhay et al. 2013; Jones et al. 2021). Similarly, feedback control using sequestration of
743 scaffold proteins was shown to enable concentration tracking of an output gene to a reference input (Hsiao et al. 2015),
744 indicating a linear input-output response (Figure 9A-ii).

745 Input-output linearization has been successful for two inducible systems (TetR/Dox and PhIF/DAPG) in mam-
746 malian cells (Szenk et al. 2020), both of which comprise the small molecule inhibiting negative autoregulation by the
747 TF. Transcriptional repressors feeding back on their own production are classically modeled as proportional feedback
748 modules. However, as the binding of a TF to a small molecule resembles a sequestration reaction, a reframing of the
749 model suggests that the topology could operate as an antithetic quasi-integral controller when the binding between the
750 TF and small molecule is faster than all other reactions and effectively irreversible. In this case, the extracellular small
751 molecule sets the reference (u), the intracellular small molecule and TF take the roles of the sequester species Z and \hat{Z} ,

752 and the mRNA for the TF is the controlled species X . In the case of TetR binding to Dox, the reverse reaction occurs
753 on the timescale of tens of hours (Schubert et al. 2004), meaning a TetR-Dox complex dissociates about as frequently
754 as the complex decays in normally-dividing mammalian cells. Further work will be needed to test if such controllers
755 are also capable of robust disturbance rejection, as expected based on the antithetic feedback topology.

756 For regenerative medicine applications, linearized sensing systems have applications in better controlling synthetic
757 or rewired signaling networks (Kojima et al. 2020). As engineered genetic circuits grow larger and more sophisticated,
758 reducing noise propagation through the circuit modules will be essential to guarantee performance across individual
759 cells. This will be especially important in applications such as cell fate programming and cell therapies, where variation
760 among individual cells can bias cell fate potential (Strebinger et al. 2019) and possibly contribute to the breaking of
761 "kill switches" and target specification moieties encoded in the therapeutic cells (Esensten et al. 2017), leading to
762 potentially deleterious therapeutic outcomes.

763 **Robustness to variable downstream loads.** Another application example of synthetic feedback control in eu-
764 karyotic cells has been in buffering against the effects of retroactivity (Mishra et al. 2014; Jayanthi and Del Vecchio
765 2011), whereby loading of a device's output by binding to downstream targets slows and disrupts the dynamics of the
766 device itself. A frequent cause of retroactivity is the binding of a TF output to the promoters of many downstream
767 target genes (Mishra et al. 2014; Jayanthi et al. 2013). By placing a "fast" buffering device between the device's TF
768 output and the downstream targets, thereby implementing a form of high-gain negative feedback, the dynamics of the
769 device's output can be decoupled from the presence of DNA target sites (Mishra et al. 2014). The high-gain feedback
770 can be implemented with a pool of rapidly-converting covalently-modified proteins that can be turned 'on' or 'off'
771 with much faster timescales than the dynamical processes in either the upstream or downstream devices (Mishra et al.
772 2014). This solution to retroactivity may be useful for regenerative medicine applications where precise control is
773 desired for a gene regulator with many downstream targets, such as lineage-specific TFs that target hundreds of sites
774 with varying access in enhancers throughout development. In such scenarios, the buffering device could potentially
775 be used to ensure a constant TF input to each individual enhancer as access of the TF to its genomic binding sites
776 fluctuates over time.

777 **Robust regulation of cell growth rate.** Finally, an emerging body of research has used controllers to decouple
778 cell growth from genetic device function. This is a particularly difficult challenge, because changes in cell growth
779 rate change the decay rates of all reasonably stable RNA and protein species (*e.g.* in mammalian cells, those with
780 half lives greater than ~ 10 hours). In turn, the operation of genetic devices can change cell growth rate (Ceroni et al.
781 2015; Jones et al. 2020). One way to approach the problem of genetic devices affecting cell growth rates has been to
782 use feedforward and/or feedback controllers to limit the burden of genetic devices on the bacterial (Ceroni et al. 2018;
783 Barajas et al. 2021) or mammalian cell (Lillacci et al. 2018) (Figure 9A-ii, C-ii), thus better optimizing the resource
784 usage of a genetic device given the constraints of the cellular environment. Note that the controller by Barajas *et al.*
785 works through regulation of ppGpp (Figure 9C-v); there is currently a limited understanding of the role of ppGpp in
786 animal cells (Ito et al. 2020), and thus the device may not be directly translatable to mammalian cells. However, the
787 general principle could be applied to boost availability of other types of shared resources to offset loading of such
788 resources.

789 Additionally, the cell growth rate itself as a function of environmental perturbations such as temperature changes
790 has been controlled in bacteria via feedback control (Aoki et al. 2019). Note that the device built by Aoki *et al.*
791 operates via antithetic feedback with sigma factors (Figure 9B-iii), which are bacteria-specific, though the topology
792 could potentially be extended to homologous general TFs in mammalian cells or to gene-specific TFs that bind form

793 high-affinity and inactive heterodimers. Future work will be needed to extend this solution to the mammalian cell cycle,
794 which has much more complex regulation (Satyanarayana and Kaldis 2009). Fortunately for mammalian synthetic
795 biologists, mammalian cells generally grow and divide much more slowly than bacteria and yeast, limiting the severity
796 of effects on the transcriptome and proteome caused by changes in cell growth rates. Whereas many molecular species
797 in mammalian cells have a decay rate that is dominated by degradation and thus insensitive to growth rate changes, the
798 decay rates of molecular species in fast-dividing organisms are significantly affected by dilution due to cell growth.

799 For future applications, ensuring robust device function in response to changing cell growth rate will facilitate
800 the translation of genetic device designs from fast-dividing cells like PSCs and HEKs to slower-dividing cells, non-
801 dividing cells, and even cells that will variably grow and divide in response to environmental conditions. Limiting
802 the effect of genetic devices on cell growth rates may also be particularly relevant for programming cell development,
803 wherein developmental progression is intricately tied to the decay rate of staged gene regulators (Rayon et al. 2020).

804 **Future development and applications of context-aware design**

805 **Applying control across biological scales**

806 Given the complexities and interconnected nature of perturbations that impact synthetic devices during cell fate
807 programming, there is an opportunity to build synthetic devices that are aware of context effects at all three levels:
808 genetic, cellular, and extracellular context. These multi-scale context-aware devices would include deliberate and
809 direct connections between the device and the cell's changing state (**Figure 10A**).

810 **Optimizing design of individual genes.** At the genetic level, CRISPR and landing pads (Duportet et al. 2014;
811 Gaidukov et al. 2018) can be used to integrate genes into "safe harbor" loci that are resistant to silencing, or that
812 become selectively active during specific stages of cellular development. Random-integration methods like lentiviruses
813 and transposons can be made more resistant to epigenetic changes through the use of chromatin insulators (Chung
814 et al. 1997; Liebert and Ellis 2005; Bortle and Corces 2012; Liu et al. 2015). Devices that synthetically regulate
815 epigenetic states of chromatin and DNA are emerging for synthetic control of gene expression and protection from
816 epigenetic effects (Thakore et al. 2016; Park et al. 2019). Additionally, the cell-to-cell variability in expression caused
817 by copy number variation among cells engineered with lentiviral, transposon, and episomal vectors may be effectively
818 eliminated through the use of feedforward controllers (Bleris et al. 2011; Lillacci et al. 2018; Jones et al. 2020). At
819 the cellular and extracellular level, feedback and feedforward controllers may be used to make expression of the gene
820 robust to changes in the myriad cellular resources that direct gene expression (Jones et al. 2020; Frei et al. 2020a;
821 Jones et al. 2021), off-target interactions from endogenous gene regulators (Jones et al. 2021), and changes in the
822 cellular environment (Aoki et al. 2019). Tools such as LOCKR feedback control (Ng et al. 2019) (Figure 9A-iii) will
823 also enable robust interrogation and control of existing gene networks and signaling pathways, furthering our ability
824 to integrate synthetic and natural systems. Controllers and context-aware design more generally offers a solution to
825 quantify the underlying physical consequences of these context effects on gene expression, and design systems that are
826 robust to the context-dependent parameters and variables. However, since adding genetic controllers can substantially
827 increase the complexity and resource demand of genetic devices, bioengineers will have to maximize the utility of
828 their systems by identifying and designing around the dominant sources of context-dependence in their systems.

829 **Controlling gene networks.** For each gene in the network, the above context effects and solutions for solving
830 them can be utilized. However, the goal of cell engineering is more often to achieve a desired cellular function, with
831 the expression state of a given gene being simply one piece of the puzzle. Ensuring that a network can properly make
832 one or more input-output calculations is a difficult task with few demonstrated bioengineering solutions (Chen et al.
833 2015; Veliz-Cuba et al. 2015; Aoki et al. 2019). At a high level, feedback and feedforward control can be used in the
834 same abstract manner to sense the inputs and/or outputs to a network and feed in control signals to correct network
835 behavior (**Figure 10A**). In this case, the behavior to be corrected can be a molecular output of the network, or the
836 confluence of many such outputs that collectively classify network status.

837 **Interfacing tissues, organs, and whole organisms.** Finally, extending the network to that of multiple cells in
838 a tissue, tissues in an organ, or organs in an organism, we can apply the same controls framework to build robust
839 multicellular systems. In this case, the individual cells communicate with each other through signaling molecules and
840 other means of cell-cell communication (Youk and Lim 2014; Teague et al. 2016; Toda et al. 2019; Kojima et al.
841 2020). Individual cells or subsets of cells sense the various inputs coming from other cells and make decisions about
842 what outputs to produce in response. This picture brings us to the point of engineering systems that can function like
843 homeostatic regulators in the human body. In future therapies where we deliver synthetic cells, tissues, and/or organs
844 as therapies, we will need to encode robust behavior at all levels, ranging from regulation of our engineered genes in
845 the designer cells/tissues/organs all the way up to how these organs interact with their host to ensure both safety and
846 efficacy. To achieve this goal, we can utilize synthetic genetic devices for engineering cell-cell communication. Such
847 tools including synthetic Notch receptors (synNotch) for sensing contact with specific cell types (Morsut et al. 2016), as
848 well as synthetic soluble factor sensing systems (Kojima et al. 2020; Maze and Benenson 2019; Scheller et al. 2020).
849 Mirroring natural morphological networks (Li et al. 2018), individual cells programmed with feedback controlled-
850 networks to respond to signaling molecules will be useful for robustly generating tissue patterns and structures. Besides
851 controlling specific cell behaviors, controllers can also be used to regulate the growth and survival of populations of
852 cells (Ma et al. 2020), which one could imagine using to self-limit therapeutic cells that can be toxic if overactive
853 (Lundh et al. 2020).

854 **Applications of context-aware genetic controllers for cell therapy development**

855 Moving forward, we can imagine synthetic biology, control systems, and context-aware design becoming more
856 broadly applicable to the entire pipeline of cell therapy development, from discovery to manufacturing to transplanta-
857 tion. Here, we will lay out a vision for a PSC-derived immune cell therapy for cancer as an example, but this process
858 could be applied to efforts in treating psoriasis (Schukur et al. 2015) and diabetes (Ye et al. 2016; Xie et al. 2016),
859 among other conditions (Kitaada et al. 2018; Scheller and Fussenegger 2019; Kojima et al. 2020).

860 **Prototyping therapeutic programs.** In the discovery stage of cell therapy development, synthetic biology offers
861 tools for building and screening various genetic devices for detection and actuation of therapeutic actions. Biosensors
862 and the genetic/cellular responses that they generate are the basic building blocks of a cell therapy that can sense and
863 respond to cues in the body. Controllers can be applied when developing such sensors in order to linearize their I/O
864 responses (Sturm et al. 2010; Nevozhay et al. 2013; Nunns and Goentoro 2018; Szenk et al. 2020), decrease noise
865 (Dublanche et al. 2006; Jones et al. 2021), and ensure that the sensor functions are robust to perturbations (Müller
866 et al. 2019; Steel et al. 2019; Jones et al. 2021). Thus, controllers can help both in the development of devices with
867 ideal properties, as well as in ultimately yielding systems that will be more likely to work in varying contexts, such as

868 when moved from cell lines (*e.g.* Jurkat T-cells) to primary cells, or when *in vitro* tests with those engineered primary
869 cells are moved *in vivo*.

870 **Cell manufacturing.** For the manufacturing stage of allogeneic (or off-the-shelf) cell therapies (**Figure 10B**),
871 PSC-derived cells must follow defined developmental trajectories to reach the desired cell type. In the case of T
872 cell derivation by directed differentiation of PSCs, controllers can help to ensure each cell autonomously receives
873 the correct signals at each stage of differentiation, by robustly linking optimized TF expression cascades to cell state
874 sensors. While current methods of niche engineering can generally provide many of these signals on time, controllers
875 can ensure that extracellular context effects, such as variable niche signals and interaction with heterogeneous cells
876 at asynchronized developmental stages and fates, will not disrupt the development of the target cell population. In
877 addition, controllers can be used to measure the current state of the cell and modulate the levels of stimuli to enforce
878 desirable cell fate transitions or prevent undesirable fates.

879 Broadening this framework to the multicellular environment of bioreactors in which PSCs are expanded and differ-
880 entiated to T cells, context-aware design can help to expand or limit the specialized cell types that develop in the cell
881 batches, avoiding the emergence of off-target cell types. For scale-up of these manufactured cells, population-limiting
882 feedback systems (Ma et al. 2020) can be used to prevent overgrowth such that ideal densities of cells are maintained
883 throughout fed-batch growths. In fact, production of effectors proteins such as CARs and cytokines by engineered T
884 cells may also be improved by optimizing the gene expression programs within the cell to avoid overburdening the
885 cell's resources (Lillacci et al. 2018). Overall, the use of controllers and context-aware engineering in cell therapy
886 production will help to increase reliability, simplify experimental conditions, and reduce costs.

887 **Controlling therapeutic cell function.** Context-aware design is particularly important for the therapeutic use
888 of cell therapies. Expected challenges such as the inability to engraft and graft-vs-host disease (GVHD) can be
889 approached by engineering signaling proteins/processes and major histocompatibility complexes in the therapeutic
890 cells (Deuse et al. 2019; Ferreira et al. 2019; Han et al. 2019; Raffin et al. 2020; Zhao et al. 2020). With control
891 systems in place, the expression of such elements can be made to adapt to the local environment, further improving the
892 chance of successful engraftment for individual cells and perhaps even entire tissues. Control systems can similarly
893 be used to ensure that therapeutic cells home to the right part of the body, for example by sensing nearby cells
894 and altering motility until locating a tumor (**Figure 10B**). Within tumors, context effects become extreme: between
895 patients and even within an individual patient's tumor, the variability in cell composition and interactions among
896 tumor, immune, and stromal cells are extremely complex, limiting the efficacy of immune and cell-based therapies
897 (Beatty and Gladney 2015; Bielamowicz et al. 2018). We thus need to design our therapeutic cells to identify and
898 kill cancer cells and recruit/stimulate other immune cells to help in a robust and reliable way. For example, we can
899 imagine sensing and outputting signals from the therapeutic cell into the tumor in order to control the overall state
900 of signaling and immune competence within the tumor microenvironment. The therapeutic cells themselves can be
901 engineered to be robust in function relative to the suppressive immune environment of the tumor, reducing problems
902 like T cell exhaustion (Martinez and Moon 2019) and other undesirable cell state changes that limit efficacy. Finally,
903 the cell therapy must be designed to maximize safety; it cannot harm the patient through problematic outcomes such as
904 cytokine release syndrome (Lundh et al. 2020). To do so, we can engineer self-limiting systems that measure the effect
905 that the therapeutic cell is having on the body as a whole and adjust effector functions as needed to prevent toxicity
906 while continuing to carry out prescribed tasks. This will require the development of sophisticated genetic systems that
907 can connect intracellular and extracellular environments and apply robust, precise regulation of signaling to the tissue
908 and body as a whole.

909 **Conclusion**

910 Through the design of genetic controllers, fundamentally rooted in control systems theory, we can develop a new
911 class of context-aware synthetic devices that are robust to the mammalian cell context. These devices and the larger
912 circuits they compose offer a new strategy for insulation from genetic, cellular and extracellular context effect by
913 viewing them as perturbations. With this new class of context-aware devices comes exciting opportunities to engineer
914 therapeutically-relevant cells that have fundamentally predictable behaviors, both in manufacturing pipelines and upon
915 transplantation into patients.




Figure 1: Viewing the cell as a programmable unit.




Figure 2: Outside-in and inside-out approaches to cell engineering.




Figure 3: Detailed breakdown of a genetic device.




Figure 4: The genetic device is the core unit of synthetic biology.




Figure 5: The mammalian cell context imposes context effects that challenge the function of genetic devices.




Figure 6: Genetic controllers adapt genetic device outputs to disturbances.





Figure 9: Feedback and feedforward controller implementations.

A Scale of genetic control from genes to GRNs to tissues



B Applications of context-aware design for cell therapies

	Cell manufacturing: Optimizing cell fate programming trajectories	Controlling therapeutic cell function: <i>In vivo</i> homing and population control
Goal	<ul style="list-style-type: none"> • Optimized trajectory of cell fate programming from PSC to T cell • Improved efficiency and yield of T cells for therapeutic use 	<ul style="list-style-type: none"> • Automated population size control • Tumor homing and killing • Resistance to tumor environment • Systemic sensing for self-limitation
Context-aware properties	<ul style="list-style-type: none"> • Circuit undisrupted by interactions with neighboring cells in unsynchronized states • Genetic circuit functions across cell types (cell lines to primary cells) • Circuit is robust to cell state changes • Circuit is not impacted by resource sharing effects 	<ul style="list-style-type: none"> • Circuit undisrupted by interactions with neighboring cells in changing <i>in vivo</i> environment

Figure 10: Future applications for context-aware genetic controllers in regenerative medicine.

917 **Figure Legends**

918 **Figure 1: Viewing the cell as a programmable unit.** (A) The cell is a processor that maps chemical and mechani-
919 cal inputs from the cellular microenvironment – cell-cell interactions, interactions with the extracellular matrix (ECM),
920 and soluble factors – to phenotypic outputs. The processing activity of the cell is enabled through the regulatory net-
921 work, composed of molecular players (DNA, RNA, and proteins) that interact via biochemical reactions to facilitate
922 dynamical processes, including transcription, translation, and modifications to the players involved. Synthetic genetic
923 circuits (green) are incorporated into the endogenous molecular network (blue) to enant new function. (B) Cell fate
924 trajectory is driven by the state of the cellular processor, environmental inputs, and sources of stochasticity. Cells can
925 be visualized on the classic Waddington landscape, moving from an initial state as they roll down the hill and stabilize
926 in valleys representing the final cell state. Reprogramming, the conversion of somatic cells to pluripotent stem cells,
927 is often visualized as a movement up the Waddington landscape as the cells gain potency, while differentiation is de-
928 picted by a movement downwards. (C) Synthetic biology offers a framework for programming the inner regulatory
929 network of the cell, allowing for predictable cell fate changes to occur, leading cells to a desired target state.

930 **Figure 2: Outside-in and inside-out approaches to cell engineering.** Outside-in and inside-out engineering
931 represent complementary approaches for cellular engineering. Niche engineering represents an "outside-in" approach,
932 where the cellular microenvironment is programmed through the addition of native or synthetic extracellular signals
933 such as cytokines, small molecules, and engineered cellular matrices. These environmental cues provide chemical
934 and mechanical inputs into the cellular processor, thus driving phenotype. On the other hand, genetic engineering
935 approaches to cell fate programming represent an "inside-out" approach, where portions of the cellular processor are
936 manipulated: either the receptors and signaling pathways (pathway engineering) or the regulatory networks themselves
937 (regulatory gene network engineering).

938 **Figure 3: Detailed breakdown of a genetic device.** (A) Zooming in on the genetic device constituting one
939 node in a larger network. The basic genetic device represents one gene encoded on a strand of DNA D_X , which is
940 transcribed to generate an mRNA M_X , which is translated to a protein X . After translation, X can be regulated via
941 the addition or removal of post-translational modifications (PTMs) to X^* . Common PTMs include phosphate group
942 addition/removal by kinases/phosphatase and ubiquitination by ubiquitin ligases (ULs). The output (Y) of the genetic
943 device can be any of the species produced by the gene that feed into a downstream process. Expression of the output(s)
944 is affected by specified regulatory inputs (U) and undesirable disturbance inputs (R) that can act on each of the key
945 rate processes of gene expression: transcription (α), translation (β), mRNA decay (δ), protein decay (γ), and PTM
946 addition/removal (φ). (B) Summary of the reactions involved in expression of the genetic device output(s). (C) Each
947 of the reaction rates are dependent to varying degree on sequences encoded in the DNA. These sequences can ideally
948 be combined in a modular fashion to statically engineer the reaction rates of the device. (D) The reaction rates can also
949 be regulated by dynamic inputs (U). Transcription factors (TFs) bind DNA and regulate transcription, RNA binding
950 proteins and miRNAs (miRs) bind and regulate RNA decay and translation, proteases bind and regulate protein decay,
951 and kinases/phosphatases/ULs bind and regulate protein PTMs (Del Vecchio and Murray 2014; Alberts et al. 2014;
952 Alon 2019). In Panels (C) and (D), + and ++ indicate static and dynamic design parameters that influence the indicated
953 reaction rate; ++ indicates a dominant influence on the given rate).

954 **Figure 4: The genetic device is the core unit of synthetic biology.** The genetic device provides a desirable
955 input/output response, allowing for predictable control over its temporal dynamics, dose response, and the distribution
956 of the outputs it produces. The device sits within the context of the cell's inner regulatory network, or processor,

957 which provides an input/output mapping within the context of the microenvironment. The cellular microenvironment
958 provides inputs to the cell in the form of chemical and mechanical cues from neighboring cells or from the cell
959 itself. Multicellular populations, such as tissues and organs, can also be viewed as systems that map inputs from their
960 macroenvironment to outputs, which are seen as emergent structures and functions. These emergent properties enable
961 the tissue to provide a function in the body through coordination between the cells composing the tissue.

962 **Figure 5: The mammalian cell context imposes context effects that challenge the function of genetic devices.**
963 (A) The genetic, cellular, and extracellular contexts provide sources of perturbation that interfere with the genetic
964 device's input/output performance. (B) Control systems view of the interactions between the synthetic genetic device
965 and the cellular context. Direct off-target interactions between the synthetic device and the cell's regulatory network
966 perturb both the genetic device and, indirectly, the cell state (Berger et al. 1992; Gilbert et al. 1993; Baron et al. 1997;
967 Lin et al. 2007; González et al. 2015; Gouda et al. 2019). The sharing of critical cellular resources, such as polymerases
968 and ribosomes, among synthetic and natural genetic devices creates indirect off-target interaction between the device
969 and other cellular processes (Ceroni et al. 2015; Jones et al. 2020). Connections between the synthetic genetic device
970 and other devices (whether cellular or synthetic) can lead to retroactivity (Del Vecchio et al. 2008). The synthetic
971 genetic device is also directly influenced by changes in cell state, which alter the concentration and availability of
972 endogenous and exogenous molecular components. The device may also drive both prescribed and unprescribed
973 changes to the cell state. Stochasticity due to mesoscopic fluctuations in the biochemical reactions involved in genetic
974 device activity also perturb device function. This can result from the noisy nature of gene expression (Raser and
975 O'Shea 2005), variability in DNA copy numbers (Bleris et al. 2011), and cell division partitioning error (Del Vecchio
976 and Murray 2014). (C) The genetic context imposes positional effects due to nearby transcriptional activity, such as
977 enhancers (Liu et al. 2015) and read-through (Loughran et al. 2014; Li and Zhang 2019), as well as chromatin state
978 effects, such as DNA coiling and torsional effects (Allis et al. 2007; Yeung et al. 2017; Allis and Jenuwein 2016;
979 Yeung et al. 2017).

980 **Figure 6: Using genetic controllers to adapt genetic device outputs to disturbances.** (A) There are two basic
981 architectures of controllers: feedback and feedforward. In feedback control (top), the output is compared to a set point
982 (input) and when the output level and set point are different (for example, due to disturbance inputs), the controller
983 actuates the device to change its output. In feedforward control (bottom), the controller directly senses disturbance
984 inputs and then actuates the genetic device to offset the effects of the disturbances. (B) Adaptation to disturbances
985 enabled by controllers. In response to a disturbance (d), the controller responds by actuating the device. This should
986 restore the device output to the set point at steady-state, yielding adaptation. If there is a difference between the device
987 output and set point at steady-state (nonzero steady-state error), then the controller provides imperfect adaptation to
988 disturbances. (C) Generalized structure of a feedback controller. An arbitrary controller network is connected to an
989 arbitrary controlled network (one theoretical example of each shown) via sensing of the controlled network's output
990 and actuation into one of its nodes. These controllers can achieve robustness to perturbations that affect genetic devices
991 within or upstream of the feedback loop created by the controller, so long as the perturbation affects the information
992 path between the controller actuation and sensing reactions. A benefit of feedback control is the ability to adapt
993 to any uncertainty in the controlled system itself (again, as long as perturbations are on the path between actuation
994 and sensing). This uncertainty can include uncertain parameters, noise, the effects of disturbance inputs, unmodeled
995 dynamics, and other unknowns. (D) Generalized structure of a feedforward controller. Similarly to before, arbitrary
996 controller and controlled system networks are connected, though in this case the controller senses the disturbance
997 itself rather than the output of the controlled network. These controllers can impart adaptation to disturbances that the
998 controller can sense, and have a reduced risk for instability compared to feedback controllers. However, feedforward

999 controllers cannot adapt to perturbations that affect the plant only but not the controller, such as parameter uncertainty.

1000 **Figure 9: Feedback and feedforward controller implementations.** (A) One topology capable of quasi-integral
1001 feedback control is enzymatic feedback (see **Box 2** and **Figure 7** for mathematical treatment). In this design, two
1002 factors competitively catalyze the conversion of a gene regulator between an active and inactive state. (i) A well-
1003 studied version of this controller is implemented with a kinase and phosphatase that competitively phosphorylate and
1004 dephosphorylate a TF (Chang et al. 2013; Qian and Del Vecchio 2018; Jones et al. 2021). This design has been shown
1005 capable of adapting output expression to various inputs, including input pulses (Chang et al. 2013) and off-target
1006 regulation and resource competition (Jones et al. 2021). (ii-iii) Another conception of this basic design is through
1007 enzymatically-induced decay of the controller species at either the (ii) RNA (Lillacci et al. 2018; Bloom et al. 2015) or
1008 (iii) protein (Ng et al. 2019) level. The forward reaction in this case is encapsulated by the production of the controller
1009 species. Such designs have been shown to enable adaptation of output expression to several disturbances, including
1010 copy number variation (Lillacci et al. 2018), transcriptional perturbations (Bloom et al. 2015), and induction of protein
1011 decay (Ng et al. 2019). Note that no work thus far has demonstrated *in vivo* quasi-integral control with this design. (B)
1012 Another topology capable of quasi-integral feedback control is antithetic feedback (see **Box 2** and **Figure 7** for math-
1013 ematical treatment). In this design, two controller species irreversibly bind and form an inert complex or annihilate
1014 (Briat et al. 2016). One species must be responsible for sensing the controlled system’s output and the other sensing
1015 the reference input (Aoki et al. 2019). (i) The earliest implementation of this design used scaffold and anti-scaffold
1016 proteins to dynamically track a reference input set by one of the scaffolds, which connected a kinase to a substrate
1017 (Hsiao et al. 2015). (ii-iv) In the last few years, several successful implementations of the antithetic feedback design
1018 using (ii) bacterial small RNA (sRNA) (Huang et al. 2018), (iii) bacterial sigma factors (Aoki et al. 2019), or (iv) an-
1019 tisenase RNA (Frei et al. 2020b) as the sequester species have been shown to achieve quasi-integral control and impart
1020 robustness to several perturbations. These perturbations range from changes in protein decay rates (Aoki et al. 2019;
1021 Frei et al. 2020b) to overloading of ribosome availability via resource competition (Huang et al. 2018). The design
1022 by Frei *et al.* was even shown to enable adaptation to network perturbations in the controller, demonstrating the *in*
1023 *vivo* versatility of this controller design. (C) Near-perfect adaptation to disturbances has been achieved using several
1024 feedforward control designs. Feedforward controllers have typically been made via the incoherent feedforward loop
1025 (iFFL) motif (Mangan and Alon 2003), in which an upstream node both positively and negatively regulates a down-
1026 stream node. (i) In both mammalian cells (Bleris et al. 2011) and bacteria (Segall-Shapiro et al. 2018), feedforward
1027 control using TFs has been used to offset changes in DNA copy number. The latter was highly successful due to the
1028 use of TALE repressors, which unlike many TFs do not bind to DNA cooperatively (Segall-Shapiro et al. 2018). (ii-iv)
1029 Another class of feedforward controllers have used enzymatic degradation of an output molecule via miRNAs (Bleris
1030 et al. 2011; Strovas et al. 2014; Lillacci et al. 2018; Frei et al. 2020a), proteases (Gao et al. 2018), or endoRNases
1031 (Jones et al. 2020). These designs have also enabled adaptation to DNA copy number (Bleris et al. 2011; Lillacci et al.
1032 2018; Jones et al. 2020), as well as resource competition (Frei et al. 2020a; Jones et al. 2020), transcriptional inducers
1033 (Strovas et al. 2014), and changes in protease production (Gao et al. 2018). (v) A recent study demonstrated feedfor-
1034 ward control of ribosome levels to offset loading of the ribosome by the output protein by co-expressing SpoTH, the
1035 hydrolysis domain of SpoT, a positive regulator of ribosome activity in bacteria (Barajas et al. 2021). This was shown
1036 to reduce the effects of resource loading both on other genes and on cell growth rates.

1037 **Figure 10: Future applications for context-aware genetic controllers in regenerative medicine.** (A) Context-
1038 aware genetic devices can provide robust control over the expression of genes of interest at the molecular level,
1039 while also embedded in synthetic regulatory networks that rely on control systems to direct cell state changes. These
1040 networks are further embedded in multicellular environments where feedback between engineered cells can be used

1041 to control the dynamics of the multicellular system. These layers of control allow for robust and predictable cell
 1042 behaviors to be achieved. **(B)** Context-aware genetic controllers can be applied to PSC-derived engineered T cells for
 1043 cancer therapeutics. Two examples are proposed. The first optimizes the derivation of T cells from PSCs through the
 1044 controlled overexpression of TFs, where genetic controllers provide dynamic control over the levels of these TFs that
 1045 guide individual cells along this optimal differentiation trajectory through real-time sensing of the cell's state. Finally,
 1046 controllers can be used to confer the ability of these engineered T cells to home to and trigger the selective killing of
 1047 tumour cells in the patient's body. Further, the cells can be made to engage in self-sensing to control their population
 1048 size, as well as sensing of markers of the overall systemic state, allowing the T cells to self-limit their killing activity
 1049 as needed. The functions of these circuits are made robust through context-aware circuit design, which ensures that
 1050 their functions are undisrupted by the changing cell state and microenvironment. These designs can also be used to
 1051 mitigate resource loading effects and ensure that circuit function is preserved across cell types, where initial testing
 1052 can be done in cell lines and later transitioned to PSCs.

1053 **Box 1: Near-perfect adaptation via quasi-integral feedback control**

1054 A key approach for a system to achieve perfect adaptation to disturbances is through integral feedback control
 1055 (Åström and Murray 2008; Del Vecchio and Murray 2014). With integral control, the error between the measured
 1056 output and set point is summed up over time, with the strength of the feedback actuation being proportional to the
 1057 summed (integrated) error. Thus, as the controller applies a correcting action to reduce the error, it can determine
 1058 whether to increase or decrease its correcting action depending on the persistence of the error. This contrasts most
 1059 relevantly with proportional control, in which the correcting action is proportional to the current magnitude of the
 1060 error. The memory of past error critically enables an integral controller to eliminate steady-state error and thus achieve
 1061 perfect adaptation. Proportional control cannot, alone, eliminate error, but is frequently used in combination with
 1062 integral control to improve dynamics and minimize overshoot (Åström and Murray 2008). Here we will discuss
 1063 different mechanisms by which integral control can be implemented in cells and specific implementation challenges.

1064 In general, integrators are devices that compute the difference between the levels of two different molecular species
 1065 in the cell and integrate it over time (Briat et al. 2016). Mathematically, integral controllers within reaction networks
 1066 can take the following form:

$$\begin{aligned} \frac{dX}{dt} &= \alpha \cdot f(Z) - \delta \cdot X + d_1 \\ \frac{dZ}{dt} &= K \cdot (u - X) \\ \Rightarrow Z(t) &= K \cdot \int_0^t (u - X(\tau)) \cdot d\tau, \end{aligned}$$

1067 where K encapsulates the feedback gain, u is a reference input (set point) that is compared to X , d_1 is a disturbance,
 1068 and α and δ are the production and decay rates of X , respectively. Here, the error is the difference between u and X ,
 1069 which is integrated over time, multiplied by the feedback gain K , and used to alter the concentration of Z . As long as
 1070 partial $\partial f(Z)/\partial Z > 0$, the system's equilibrium is stable and at steady state we obtain that $X = u$, independent of d_1 .

1071 A key challenge to the biological implementation of an integral function is that the controller species Z can decay

1072 through either cell division or degradation:

$$\begin{aligned}\frac{dX}{dt} &= \alpha \cdot f(Z) - \delta \cdot X + d_1 \\ \frac{dZ}{dt} &= K \cdot (u - X) - \gamma \cdot Z,\end{aligned}$$

1073 where γ is the decay rate of Z . The decay causes the integrator to become "leaky" and thus no longer correctly sums
1074 the error over time (Qian and Del Vecchio 2018). Given the omnipresence of molecule dilution and degradation, this
1075 leakiness makes perfect integrators nearly impossible to achieve within a cell. To restore the performance of a leaky
1076 integral controller, all of the controller reaction rates should be made fast compared to the decay rate of the controller
1077 species, leading to "quasi-integral" control (Qian and Del Vecchio 2018; Huang et al. 2018). In our example, quasi-
1078 integral control is possible through a large feedback gain K , leading to $Z(t) \approx K \cdot \int_0^t (u - X(\tau)) \cdot d\tau$. However, if K is
1079 too large, the controller can cause the output level to overshoot the set point and oscillate (Åström and Murray 2008;
1080 Del Vecchio and Murray 2014).

1081 There are two main types of reactions that have been proposed to implement quasi-integral control (**Figure 7**):
1082 enzymatic (left) and sequestration (right) reactions carried out by RNA or protein regulators (\hat{Z}) on RNA or protein
1083 substrates (Z). In both of these designs, the steady state level of the output can be made practically independent of
1084 all the indicated parameters, which are functions of disturbance inputs (R). Under stability conditions, for which we
1085 require $\partial f(Z)/\partial Z > 0$, the output can adapt to changes in all parameters (and thus in R) for K sufficiently large.
1086 In the enzymatic reaction implementation, to obtain the form of differential equations in **Figure 7**, it is necessary
1087 that both the forward and backward enzymatic reactions operate in the zero-order regime (Atkins and Paula 2006;
1088 Goldbeter and Koshland 1981; Del Vecchio and Murray 2014) (see derivation by Qian *et al.* (Qian and Del Vecchio
1089 2018)). The need for a zero-order regime limits the function of the system as a quasi-integral controller to conditions
1090 where the concentrations of both Z and \hat{Z} are sufficiently high. For the sequestration reaction-based design, the mutual
1091 sequestration of Z and \hat{Z} can occur either through an irreversible binding reaction in which the complex formed is non-
1092 functional or through a reversible binding reaction where the complex is irreversibly converted to an inactive species
1093 (Briat et al. 2016; Huang et al. 2018; Aoki et al. 2019). In the latter case, the concentrations of neither Z nor \hat{Z} can be
1094 in excess of one another, such that the rate of complex formation is approximately proportional to the product $Z \cdot \hat{Z}$,
1095 leading to the form of equations in **Figure 7**.

1096 In both implementations, to achieve robustness to perturbations R , it is not necessary that X enters linearly the
1097 dynamics of Z , \hat{Z} , and Z^* . Indeed, X could enter through an increasing function $g(X)$ and the same robustness property
1098 would hold. However, the quasi-integral feedback control fails to restore the output to the set point in regimes where
1099 the X becomes insensitive to Z . This can happen, for example, if Z activates the production of X and approaches
1100 saturation.




Figure 7: Basic topologies for quasi-integral feedback control

1101 **Box 2: Example of solving context-dependence with feedforward control**

1102 To solve any problem of context-dependence in engineering cell behavior, it is first necessary to identify the source
 1103 of context-dependence. For example, we identified that resource sharing, primarily at the transcriptional level, causes
 1104 expression of simple genetic devices to unexpectedly change upon introduction of other genes into mammalian cells
 1105 (Jones et al. 2020). More detailed analysis identified "squelching" to be the culprit. Squelching occurs when TFs
 1106 sequester coactivator resources from other genes, regardless of whether the TF is actively bound to its target gene or
 1107 not (Gill and Ptashne 1988; Berger et al. 1990). Thus, the effect of squelching by a TF is to reduce the transcription
 1108 rate (α) of other genes. Resource sharing can cause any rate in the expression of a gene to become coupled among
 1109 genes competing for the shared resource. Examples of such resources acting as disturbance inputs (R) to a genetic
 1110 device are given in **Figure 8A**.

1111 To decouple gene expression from transcriptional/translational resource loading, we designed a feedforward-
 1112 controlled device in which the controller senses RNA and protein production resources, R_{TX} and R_{TL} , respectively, and
 1113 then actuates the genetic device through post-transcriptional repression (**Figure 8B**). In response to changes in pro-
 1114 duction resources that are disturbance inputs to both the controller and the output, the feedforward controller actuates
 1115 an offsetting signal to maintain a set level of output expression. In our design, the controller was implemented through


1116 a protein endoRNase that enzymatically destroys the output mRNA (Jones et al. 2020), though a conceptually similar
1117 design with miRNAs instead of endoRNases can give similar robustness to loading of transcriptional resources (Frei
1118 et al. 2020a).

1119 The ability of our feedforward controller to offset changes in resource availability can be seen by analyzing the
1120 differential equations describing the system (**Figure 8C**, left). Note that here we have assumed for simplicity of
1121 illustration that the concentration of X is well below the point of saturating the action of Z , such that the degradation
1122 of X depends linearly on both X and Z .


1123 Without the controller (*i.e.* when $K = 0$, or equivalently when M and Z are absent), the expression level of the
1124 output Y is dependent on cellular resources used for both transcription (R_{TX}) and translation (R_{TL}) (**Figure 8C**, right).
1125 With the controller and for large values of K , the steady-state of Y reduces to an equation that is independent of the
1126 transcription and translation resources R_{TX} and R_{TL} , respectively (**Figure 8C**, right). Indeed, in our experimental
1127 results, we found that the controller could perfectly offset changes in resource availability caused by squelching (Jones
1128 et al. 2020).

1129 An important note is that the adaptation enabled by the controller does not necessarily hold if the change in resource
1130 availability is accompanied by a change in the growth rate of the cell. The above analysis assumes that the decay rates
1131 are constant, but such a perturbation can differentially affect the decay rate (γ) of proteins that are relatively stable such
1132 that their decay is dominated by dilution from cell growth/division (Jones et al. 2020). Most mRNAs and unstable
1133 proteins have decay rates dominated by degradation (Schwanhäusser et al. 2011), and thus are less affected by changes
1134 in cell growth. If the controller (Z) and output (Y) species have substantially different degradation rates, then changes
1135 in cell growth rate resulting from changes in resource availability will cause the γ and $\hat{\gamma}$ parameters to differentially
1136 change and perturb the observed level of output Y (Jones et al. 2020). Thus, care should be taken when implementing
1137 a feedforward controller to ensure that the effect of the disturbance on the output can be properly sensed and offset
1138 accordingly.

A Example of context-dependence: resource sharing



B Example of context-aware solution: feedforward control



C Model analysis

Generalized differential equations:

$$\frac{dM}{dt} = \hat{\alpha} \cdot R_{TX} \cdot D - \hat{\delta} \cdot M$$

$$\frac{dZ}{dt} = \hat{\beta} \cdot R_{TL} \cdot M - \hat{\gamma} \cdot Z$$

$$\frac{dX}{dt} = \alpha \cdot R_{TX} \cdot D - K \cdot Z \cdot X - \delta \cdot X$$

$$\frac{dY}{dt} = \beta \cdot R_{TL} \cdot X - \gamma \cdot Y$$

Without controller ($K = 0$): $Y = \frac{\alpha \cdot \beta}{\delta \cdot \gamma} \cdot R_{TX} \cdot R_{TL} \cdot D$

With controller ($K > 0$):

$$Y = \frac{\alpha \cdot \beta \cdot R_{TX} \cdot R_{TL} \cdot D}{\left(\delta + K \cdot \frac{\hat{\alpha} \cdot \hat{\beta}}{\hat{\delta} \cdot \hat{\gamma}} \cdot R_{TX} \cdot R_{TL} \cdot D \right) \cdot \gamma}$$

For large K :

$$Y = \frac{U}{K} \quad | \quad U = \frac{\alpha \cdot \beta}{\hat{\alpha} \cdot \hat{\beta}} \cdot \frac{\hat{\delta} \cdot \hat{\gamma}}{\gamma}$$

→ The output is robust to all resources needed for transcription (R_{TX}) and translation (R_{TL}) of both Z and Y . Note the tradeoff in robustness and output level imposed by increasing K .

Figure 8: Example of solving context-dependence with feedforward control

Acknowledgements

This work was supported by the National Institutes of Health (NIH/NIBIB Grant Number R01EB024591) and in part by a National Science Foundation RoL Award (MCB-1840257). N.S. was supported by a Postdoctoral Fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC). MIT has filed patents on behalf of R.D.J., R.W., and D.D.V. relating to the design of genetic controllers for use in mammalian cells.

References

- Ahuja, Deepika, M Teresa Sáenz-Robles, and James M Pipas (2005). SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. *Oncogene* 24.52, pp. 7729–7745.
- Ailles, Laurie, Manfred Schmidt, Francesca Romana Santoni de Sio, Hanno Glimm, Simona Cavalieri, Stefania Bruno, Wanda Piacibello, Christof Von Kalle, and Luigi Naldini (2002). Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-potent, Long-Term NOD/SCID Repopulating Hematopoietic Cells. *Molecular Therapy* 6.5, pp. 615–626.
- Alberts, Bruce, Alexander Johnson, Julian Lewis, David Morgan, Martin Raff, Keith Roberts, and Peter Walter (2014). *Molecular Biology of the Cell*. Ed. by Georgina Lucas. 6th. New York, NY: W. W. Norton & Company.
- Allis, C D, T J D R C David Allis, T Jenuwein, D Reinberg, and M L Caparros (2007). *Epigenetics*. Pediatric research. Cold Spring Harbor Laboratory Press.
- Allis, C. David and Thomas Jenuwein (2016). The molecular hallmarks of epigenetic control. *Nature Reviews Genetics* 17.8, pp. 487–500.
- Alon, U (2019). *An Introduction to Systems Biology: Design Principles of Biological Circuits*. Chapman {&} Hall/CRC Computational Biology Series. CRC Press LLC.
- Ang, Jordan, Edouard Harris, Brendan J. Hussey, Richard Kil, and David R. McMillen (2013). Tuning Response Curves for Synthetic Biology. *ACS Synthetic Biology* 2.10, pp. 547–567.
- Aoki, Stephanie K., Gabriele Lillacci, Ankit Gupta, Armin Baumschlager, David Schweingruber, and Mustafa Khammash (2019). A universal rationally-designed biomolecular integral feedback controller for robust perfect adaptation. *Nature* 570, pp. 533–537.
- Araujo, Robyn P and Lance A Liotta (2018). The topological requirements for robust perfect adaptation in networks of any size. *Nature Communications* 9.2018, p. 1757.
- Åström, Karl J. and Richard M. Murray (2008). *Feedback systems: an introduction for scientists and engineers*. Princeton University Press.
- Atkins, Peter and Julio de Paula (2006). The rates of chemical reactions. *Atkins' Physical Chemistry*. 8th. New York, NY: W.H. Freeman, pp. 791–823.
- Baker, Nicholas E (2020). Emerging mechanisms of cell competition. *Nature reviews. Genetics*, pp. 1–15.
- Balázsi, Gábor, Alexander van Oudenaarden, and James J. Collins (2011). Cellular Decision Making and Biological Noise: From Microbes to Mammals. *Cell* 144.6, pp. 910–925.
- Barajas, Carlos, Jesse Gibson, Luis Sandoval, and Domitilla Del Vecchio (2021). A burden-free gene overexpression system, Preprint at <https://www.biorxiv.org/content/10.1101/2021.02.11.430724v1>.
- Barajas, Carlos and Domitilla Del Vecchio (2020). Effects of spatial heterogeneity on bacterial genetic circuits. *PLOS Computational Biology* 16.9, e1008159.
- Barkai, N. and S. Leibler (1997). Robustness in simple biochemical networks. *Nature* 387.6636, pp. 913–917.

1178 Baron, Udo, Manfred Gossen, and Hermann Bujard (1997). Tetracycline-controlled transcription in eukaryotes: Novel
1179 transactivators with graded transactivation potential. *Nucleic Acids Research* 25.14, pp. 2723–2729.

1180 Beal, Jacob, Tyler E Wagner, Tasuku Kitada, Odizze Azazgolshani, Jordan Moberg Parker, Douglas Densmore, Ron
1181 Weiss, Odisse Azizgolshani, Jordan Moberg Parker, Douglas Densmore, and Ron Weiss (2014). Model-driven
1182 Engineering of Gene Expression from RNA Replicons. *ACS Synthetic Biology* 4, pp. 48–56.

1183 Beatty, Gregory L. and Whitney L. Gladney (2015). Immune escape mechanisms as a guide for cancer immunotherapy.
1184 *Clinical Cancer Research* 21.4, pp. 687–692.

1185 Becskel, Attila and Luis Serrano (2000). Engineering stability in gene networks by autoregulation. *Nature* 405.6786,
1186 pp. 590–593. arXiv: 9810036 [physics].

1187 Berger, Shelley L., W. Douglas Cress, Andrea Cress, Steven J. Triezenberg, and Leonard Guarente (1990). Selective
1188 inhibition of activated but not basal transcription by the acidic activation domain of VP16: Evidence for transcrip-
1189 tional adaptors. English. *Cell* 61.7, pp. 1199–1208.

1190 Berger, Shelley L., Benjamin Piña, Neal Silverman, Gregory A. Marcus, Julie Agapite, Jeffrey L. Regier, Steven J.
1191 Triezenberg, and Leonard Guarente (1992). Genetic isolation of ADA2: a potential transcriptional adaptor required
1192 for function of certain acidic activation domains. *Cell* 70, pp. 251–265.

1193 Bhalla, Upinder S. and Ravi Iyengar (1999). Emergent Properties of Networks of Biological Signaling Pathways.
1194 *Science* 283.5400, pp. 381–387.

1195 Bielamowicz, Kevin, Kristen Fousek, Tiara T. Byrd, Hebatalla Samaha, Malini Mukherjee, Nikita Aware, Meng Fen
1196 Wu, Jordan S. Orange, Pavel Sumazin, Tsz Kwong Man, Sujith K. Joseph, Meenakshi Hegde, and Nabil Ahmed
1197 (2018). Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. *Neuro-Oncology* 20.4,
1198 pp. 506–518.

1199 Bintu, Lacramioara, John Yong, Yaron E. Antebi, Kayla McCue, Yasuhiro Kazuki, Narumi Uno, Mitsuo Oshimura,
1200 and Michael B. Elowitz (2016). Dynamics of epigenetic regulation at the single-cell level. *Science* 351.6274,
1201 pp. 720–724.

1202 Black, Joshua B., Pablo Perez-Pinera, and Charles A. Gersbach (2017). Mammalian Synthetic Biology: Engineering
1203 Biological Systems. *Annual Review of Biomedical Engineering* 19.1, pp. 249–277.

1204 Bleris, Leonidas, Zhen Xie, David Glass, Asa Adadey, Eduardo Sontag, and Yaakov Benenson (2011). Synthetic in-
1205 coherent feedforward circuits show adaptation to the amount of their genetic template. *Molecular Systems Biology*
1206 7, p. 519.

1207 Bloom, Ryan J., Sally M. Winkler, and Christina D. Smolke (2015). Synthetic feedback control using an RNAi-based
1208 gene-regulatory device. *Journal of Biological Engineering* 9, p. 5.

1209 Bokhoven, Marieke, Sam L. Stephen, Sean Knight, Evelien F. Gevers, Iain C. Robinson, Yasuhiro Takeuchi, and Mary
1210 K. Collins (2009). Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors. *Journal of Virology*
1211 83.1, pp. 283–294.

1212 Bortle, Kevin Van and Victor G Corces (2012). tDNA insulators and the emerging role of TFIIC in genome organiza-
1213 tion. *Transcription* 3.6, pp. 1–8.

1214 Boudreau, Ryan L., Inês Martins, and Beverly L. Davidson (2009). Artificial microRNAs as siRNA shuttles: improved
1215 safety as compared to shRNAs in vitro and in vivo. *Molecular Therapy* 17.1, pp. 169–175.

1216 Briat, Corentin, Ankit Gupta, and Mustafa Khammash (2016). Antithetic Integral Feedback Ensures Robust Perfect
1217 Adaptation in Noisy Bimolecular Networks. *Cell Systems* 2.1, pp. 15–26. arXiv: 1410.6064.

1218 Castanotto, Daniela, Kumi Sakurai, Robert Lingeman, Haitang Li, Louise Shively, Lars Aagaard, Harris Soifer, Anne
1219 Gatignol, Arthur Riggs, and John J. Rossi (2007). Combinatorial delivery of small interfering RNAs reduces RNAi
1220 efficacy by selective incorporation into RISC. *Nucleic Acids Research* 35.15, pp. 5154–5164.

- 1221 Cella, Federica, Liliana Wroblewska, Ron Weiss, and Velia Siciliano (2018). Engineering protein-protein devices for
1222 multilayered regulation of mRNA translation using orthogonal proteases in mammalian cells. *Nature Communica-*
1223 *tions* 9.4392, pp. 1–9.
- 1224 Ceroni, Francesca, Rhys Algar, Guy-Bart Stan, and Tom Ellis (2015). Quantifying cellular capacity identifies gene
1225 expression designs with reduced burden. *Nature Methods* 12.5, pp. 415–418.
- 1226 Ceroni, Francesca, Alice Boo, Simone Furini, Thomas E Goroehowski, Olivier Borkowski, Yaseen N Ladak, Ali R
1227 Awan, Charlie Gilbert, Guy-Bart Stan, and Tom Ellis (2018). Burden-driven feedback control of gene expression.
1228 *Nature Methods* 15.5, pp. 387–393.
- 1229 Chakra, Maria Abou, Ruth Isserlin, Thinh Tran, and Gary D. Bader (2020). *Control of tissue development by cell cycle*
1230 *dependent transcriptional filtering*. Tech. rep., p. 2020.02.25.964650.
- 1231 Chang, Yo Cheng, Judith P. Armitage, Antonis Papachristodoulou, and George H. Wadhams (2013). A single phos-
1232 phatase can convert a robust step response into a graded, tunable or adaptive response. *Microbiology* 159, pp. 1276–
1233 1285.
- 1234 Cheedipudi, Sirisha, Oriana Genolet, and Gergana Dobreva (2014). Epigenetic inheritance of cell fates during embry-
1235 onic development. *Frontiers in Genetics* 5, p. 19.
- 1236 Chen, Ye, Jae Kyoung Kim, Andrew J. Hirning, Krešimir Josić, and Matthew R. Bennett (2015). Emergent genetic
1237 oscillations in a synthetic microbial consortium. *Science* 349.6251, pp. 986–989.
- 1238 Chen, Zibo, Ryan D. Kibler, Andrew Hunt, Florian Busch, Jocelynn Pearl, Mengxuan Jia, Zachary L. VanAernum,
1239 Basile I.M. Wicky, Galen Dods, Hanna Liao, Matthew S. Wilken, Christie Ciarlo, Shon Green, Hana El-Samad,
1240 John Stamatoyannopoulos, Vicki H. Wysocki, Michael C. Jewett, Scott E. Boyken, and David Baker (2020). De
1241 novo design of protein logic gates. *Science* 368.6486, pp. 78–84.
- 1242 Cheng, Joseph K., Nicholas J. Morse, James M. Wagner, Scott K. Tucker, and Hal S. Alper (2019). Design and
1243 Evaluation of Synthetic Terminators for Regulating Mammalian Cell Transgene Expression. *ACS Synthetic Biology*
1244 8, pp. 1263–1275.
- 1245 Chung, Jay H., Adam C. Bell, and Gary Felsenfeld (1997). Characterization of the chicken β -globin insulator. *Pro-*
1246 *ceedings of the National Academy of Sciences of the United States of America* 94.2, pp. 575–580.
- 1247 Clavería, Cristina, Giovanna Giovinazzo, Rocío Sierra, and Miguel Torres (2013). Myc-driven endogenous cell com-
1248 petition in the early mammalian embryo. *Nature* 500.7460, pp. 39–44.
- 1249 Cong, Le, F Ann Ran, David Cox, Shuailiang Lin, Robert Barretto, Naomi Habib, Patrick D Hsu, Xuebing Wu,
1250 Wenyan Jiang, Luciano A Marraffini, and Feng Zhang (2013). Multiplex genome engineering using CRISPR/Cas
1251 systems. English. *Science* 339.6121, pp. 819–823.
- 1252 Cookson, Natalie A., William H. Mather, Tal Danino, Octavio Mondragón-Palomino, Ruth J. Williams, Lev S. Tsim-
1253 ring, and Jeff Hasty (2011). Queueing up for enzymatic processing: Correlated signaling through coupled degra-
1254 dation. *Molecular Systems Biology* 7.1.
- 1255 Cottrell, Kyle A., Pawel Szczesny, and Sergej Djuranovic (2017). Translation efficiency is a determinant of the mag-
1256 nitude of miRNA-mediated repression. *Scientific Reports* 7.1, p. 14884.
- 1257 Courey, Albert J. (2008). *Mechanisms in Transcriptional Regulation*. 1st. Malden, MA: Blackwell Publishing.
- 1258 D’Antonio, Matteo, Paola Benaglio, David Jakubosky, William W Greenwald, Hiroko Matsui, Margaret K R Donovan,
1259 He Li, Erin N Smith, Agnieszka D’Antonio-Chronowska, and Kelly A Frazer (2018). Insights into the Mutational
1260 Burden of Human Induced Pluripotent Stem Cells from an Integrative Multi-Omics Approach. English. *Cell Re-*
1261 *ports* 24.4, pp. 883–894.
- 1262 Darlington, Alexander P.S., Juhyun Kim, José I. Jiménez, and Declan G. Bates (2018). Dynamic allocation of orthog-
1263 onal ribosomes facilitates uncoupling of co-expressed genes. *Nature Communications* 9, p. 695.

1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305

Davidson, Eric H. and Isabelle S. Peter (2015). Genomic Control Process, pp. 41–77.

De Nijs, Yatti, Sofie L. De Maeseneire, and Wim K. Soetaert (2020). 5' Untranslated Regions: the Next Regulatory Sequence in Yeast Synthetic Biology. *Biological Reviews* 95.2, pp. 517–529.

Dejosez, Marion, Hiroki Ura, Vicky L Brandt, and Thomas P Zwaka (2013). Safeguards for cell cooperation in mouse embryogenesis shown by genome-wide cheater screen. English. *Science* 341.6153, pp. 1511–1514.

Del Vecchio, Domitilla (2015). Modularity, context-dependence, and insulation in engineered biological circuits. *Trends in Biotechnology* 33.2, pp. 111–119.

Del Vecchio, Domitilla, Hussein Abdallah, Yili Qian, and James J. Collins (2017). A Blueprint for a Synthetic Genetic Feedback Controller to Reprogram Cell Fate. *Cell Systems* 4.1, 109–120.e11.

Del Vecchio, Domitilla, Aaron J. Dy, and Yili Qian (2016). Control theory meets synthetic biology. *Journal of the Royal Society Interface* 13.120.

Del Vecchio, Domitilla and Richard M. Murray (2014). *Biomolecular Feedback Systems*. 1.1b. Princeton University Press.

Del Vecchio, Domitilla, Alexander J Ninfa, and Eduardo D Sontag (2008). Modular cell biology: retroactivity and insulation. *Molecular Systems Biology* 4, p. 161.

Deuse, Tobias, Xiaomeng Hu, Alessia Gravina, Dong Wang, Grigol Tediashvili, Chandrav De, William O. Thayer, Angela Wahl, J. Victor Garcia, Hermann Reichenspurner, Mark M. Davis, Lewis L. Lanier, and Sonja Schrepfer (2019). Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. *Nature Biotechnology* 37.3, pp. 252–258.

DiAndreth, Breanna, Noreen Wauford, Eileen Hu, Sebastian Palacios, and Ron Weiss (2019). PERSIST: A programmable RNA regulation platform using CRISPR endoRNases, Preprint at <https://www.biorxiv.org/content/10.1101/2019.12.15.86>

Díaz-Díaz, Covadonga, Laura Fernandez de Manuel, Daniel Jimenez-Carretero, María Concepción Montoya, Cristina Clavería, and Miguel Torres (2017). Pluripotency Surveillance by Myc-Driven Competitive Elimination of Differentiating Cells. English. *Developmental cell*.

Donahue, Patrick S., Joseph W Draut, Joseph J Muldoon, Hailey I Edelman, Neda Bagheri, and Joshua Nathaniel Leonard (2020). COMET: A toolkit for composing customizable genetic programs in mammalian cells. *Nature Communications* 11, p. 779.

Dublanche, Yann, Konstantinos Michalodimitrakis, Nico Kümmerer, Mathilde Foglierini, and Luis Serrano (2006). Noise in transcription negative feedback loops: Simulation and experimental analysis. *Molecular Systems Biology* 2, p. 41.

Dunn, S-J, G Martello, B Yordanov, S Emmott, and A G Smith (2014). Defining an essential transcription factor program for naïve pluripotency. English. *Science* 344.6188, pp. 1156–1160.

Duportet, X., L. Wroblewska, P. Guye, Y. Li, J. Eyquem, J. Rieders, T. Rimchala, G. Batt, and R. Weiss (Nov. 2014). A platform for rapid prototyping of synthetic gene networks in mammalian cells. *Nucleic Acids Research* 42.21, pp. 13440–13451.

Ede, Christopher, Ximin Chen, Meng Yin Lin, and Yvonne Y. Chen (2016). Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells. *ACS Synthetic Biology* 5.5, pp. 395–404.

Ehrhardt, Anja, Rudolf Haase, Aloys Schepers, Manuel Deutsch, Hans Lipps, and Armin Baiker (2008). Episomal Vectors for Gene Therapy. *Current Gene Therapy* 8.3, pp. 147–161.

Elowitz, Michael B and Stanislas Leibler (2000). A synthetic oscillatory network of transcriptional regulators. *Nature* 403.6767, pp. 335–338.

1306 Emmert-Streib, Frank, Matthias Dehmer, and Benjamin Haibe-Kains (2014). Gene regulatory networks and their
1307 applications: understanding biological and medical problems in terms of networks. *Frontiers in Cell and Develop-*
1308 *mental Biology* 2, p. 38.

1309 Eisensten, Jonathan H., Jeffrey A. Bluestone, and Wendell A. Lim (2017). Engineering Therapeutic T Cells: From
1310 Synthetic Biology to Clinical Trials. *Annual Review of Pathology: Mechanisms of Disease* 12.1, pp. 305–330.

1311 Eyquem, Justin, Jorge Mansilla-Soto, Theodoros Giavridis, Sjoukje J.C. Van Der Stegen, Mohamad Hamieh, Kristen
1312 M. Cunanan, Ashlesha Odak, Mithat Gönen, and Michel Sadelain (2017). Targeting a CAR to the TRAC locus
1313 with CRISPR/Cas9 enhances tumour rejection. *Nature* 543.7643, pp. 113–117.

1314 Farzadfard, Fahim, Nava Gharaei, Yasutomi Higashikuni, Giyoung Jung, Jicong Cao, and Timothy K Lu (2019).
1315 Single-Nucleotide-Resolution Computing and Memory in Living Cells. *Molecular cell* 75.4, 769–780.e4.

1316 Ferreira, Leonardo M. R., Yannick D. Muller, Jeffrey A. Bluestone, and Qizhi Tang (2019). Next-generation regulatory
1317 T cell therapy. *Nature Reviews Drug Discovery*.

1318 Ferrell, James E (2016). Perfect and near-perfect adaptation in cell signaling. *Cell Systems* 2, pp. 62–67.

1319 Fisher, Andrew J. and Peter A. Beal (2018). Structural basis for eukaryotic mRNA modification. *Current Opinion in*
1320 *Structural Biology* 53, pp. 59–68.

1321 Fontana, Jason, Chen Dong, Jennifer Y. Ham, Jesse G. Zalatan, and James M. Carothers (2018). Regulated Expression
1322 of sgRNAs Tunes CRISPRi in *E. coli*. *Biotechnology Journal* 13.9.

1323 Frei, Timothy, Federica Cella, Fabiana Tedeschi, Joaquín Gutiérrez, Guy Bart Stan, Mustafa Khammash, and Velia
1324 Siciliano (2020a). Characterization and mitigation of gene expression burden in mammalian cells. *Nature Com-*
1325 *munications* 11, p. 4641.

1326 Frei, Timothy, Ching-Hsiang Chang, Maurice Filo, and Mustafa Khammash (2020b). Genetically Engineered Integral
1327 Feedback Controllers for Robust Perfect Adaptation in Mammalian Cells, Preprint at <https://doi.org/10.1101/2020.12.06.412304>.

1328 Gaber, Rok, Tina Lebar, Andreja Majerle, Branko Šter, Andrej Dobnikar, Mojca Benčina, and Roman Jerala (2014).
1329 Designable DNA-binding domains enable construction of logic circuits in mammalian cells. *Nature Chemical*
1330 *Biology* 10.3, pp. 203–208.

1331 Gaidukov, Leonid, Liliana Wroblewska, Brian Teague, Tom Nelson, Xin Zhang, Yan Liu, Kalpana Jagtap, Selamawit
1332 Mamo, Wen Allen Tseng, Alexis Lowe, Jishnu Das, Kalpanie Bandara, Swetha Baijuraraj, Nevin M Summers,
1333 Timothy K Lu, Lin Zhang, and Ron Weiss (2018). A multi-landing pad DNA integration platform for mammalian
1334 cell engineering. *Nucleic Acids Research* 46.8, pp. 4072–4086.

1335 Gam, Jeremy J., Breanna DiAndreth, Ross D. Jones, Jin Huh, and Ron Weiss (2019). A ‘poly-transfection’ method for
1336 rapid, one-pot characterization and optimization of genetic systems. *Nucleic Acids Research* 47.18, e106.

1337 Gam, Jeremy J, Jonathan Babb, and Ron Weiss (2018). A mixed antagonistic/synergistic miRNA repression model
1338 enables accurate predictions of multi-input miRNA sensor activity. *Nature Communications* 9, p. 2430.

1339 Gao, Xiaojing J., Lucy S. Chong, Matthew S. Kim, and Michael B. Elowitz (2018). Programmable protein circuits in
1340 living cells. *Science* 361, pp. 1252–1258.

1341 Gardner, Timothy S., Charles R. Cantor, and James J. Collins (2000). Construction of a genetic toggle switch in
1342 *Escherichia coli*. *Nature* 403.6767, pp. 339–342.

1343 Gerrits, Alice, Brad Dykstra, Olga J. Kalmykova, Karin Klauke, Evgenia Verovskaya, Mathilde J. C. Broekhuis,
1344 Gerald de Haan, and Leonid V. Bystrykh (2010). Cellular barcoding tool for clonal analysis in the hematopoietic
1345 system. *Blood* 115.13, pp. 2610–2618.

1346 Gilbert, David M., David M. Heery, Regine Losson, Pierre Chambon, and Yves Lemoine (1993). Estradiol-inducible
1347 squelching and cell growth arrest by a chimeric VP16-estrogen receptor expressed in *Saccharomyces cerevisiae*:
1348 suppression by an allele of PDR1. *Molecular and Cellular Biology* 13.1, pp. 462–472.

1349 Gill, G and M Ptashne (1988). Negative effect of the transcriptional activator GAL4. *Nature* 334.6184, pp. 721–724.

1350 Goldbeter, Albert and Daniel E. Koshland (1981). An amplified sensitivity arising from covalent modification in
1351 biological systems. *PNAS* 78.11, pp. 6840–6844.

1352 González, Caleb, Joe Christian J Ray, Michael Manhart, Rhys M Adams, Dmitry Nevozhay, Alexandre V Morozov,
1353 and Gábor Balázs (2015). Stress-response balance drives the evolution of a network module and its host genome.
1354 *Molecular Systems Biology* 11.8, p. 827.

1355 Gouda, Mirna Kheir, Michael Manhart, and Gábor Balázs (2019). Evolutionary regain of lost gene circuit function.
1356 *PNAS* 116.50, pp. 25162–25171.

1357 Grigliatti, T. and R.C. Mottus (2013). Positional Effects. *Brenner’s Encyclopedia of Genetics (Second Edition)* PLoS
1358 ONE3122008, pp. 418–420.

1359 Grimm, Dirk, Konrad L. Streetz, Catherine L. Jopling, Theresa A. Storm, Kusum Pandey, Corrine R. Davis, Patricia
1360 Marion, Felix Salazar, and Mark A. Kay (2006). Fatality in mice due to oversaturation of cellular microRNA/short
1361 hairpin RNA pathways. *Nature* 441, pp. 537–541.

1362 Grosjean, Henri (2005). Fine-tuning of RNA functions by modification and editing. *Topics in Current Genetics*. Ed. by
1363 Henri Grosjean. Vol. 24. Berlin, Heidelberg: Springer, p. 442.

1364 Guye, Patrick, Mohammad R Ebrahimkhani, Nathan Kipniss, Jeremy J Velazquez, Eldi Schoenfeld, Samira Kiani,
1365 Linda G Griffith, and Ron Weiss (2016). Genetically engineering self-organization of human pluripotent stem cells
1366 into a liver bud-like tissue using Gata6. *Nature Communications* 7, p. 10243.

1367 Gyorgy, Andras, Jose I. Jimenez, John Yazbek, Hsin Ho Huang, Hattie Chung, Ron Weiss, and Domitilla Del Vecchio
1368 (2015). Isocost Lines Describe the Cellular Economy of Genetic Circuits. *Biophysical Journal* 109.3, pp. 639–646.

1369 Haberle, Vanja and Alexander Stark (2018). Eukaryotic core promoters and the functional basis of transcription initi-
1370 ation. *Nature Reviews Molecular Cell Biology* 19, pp. 621–637.

1371 Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, M. P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C. S. Osborne,
1372 R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J. I. Cohen, G. de Saint Basile, I. Alexander, U.
1373 Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E.
1374 Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L. E. Leiva, M. Wissler, C. Prinz, T. H. Rabbitts, F. Le Deist,
1375 A. Fischer, and M. Cavazzana-Calvo (2003). LMO2-Associated Clonal T Cell Proliferation in Two Patients after
1376 Gene Therapy for SCID-X1. *Science* 302.5644, pp. 415–419.

1377 Han, Xiao, Mengning Wang, Songwei Duan, Paul J. Franco, Jennifer Hyoje Ryu Kenty, Preston Hedrick, Yulei Xia,
1378 Alana Allen, Leonardo M.R. Ferreira, Jack L. Strominger, Douglas A. Melton, Torsten B. Meissner, and Chad A.
1379 Cowan (2019). Generation of hypoinmunogenic human pluripotent stem cells. *PNAS* 116.21, pp. 10441–10446.

1380 Hao, Nan, Keith E. Shearwin, and Ian B. Dodd (2019). Positive and Negative Control of Enhancer-Promoter Interac-
1381 tions by Other DNA Loops Generates Specificity and Tunability. *Cell Reports* 26.9, 2419–2433.e3.

1382 Hartwell, Leland H., John J. Hopfield, Stanislas Leibler, and Andrew W. Murray (1999). From molecular to modular
1383 cell biology. *Nature* 402.Suppl 6761, pp. C47–C52.

1384 Hashimoto, Masakazu and Hiroshi Sasaki (2019). Epiblast Formation by TEAD-YAP-Dependent Expression of Pluripo-
1385 tency Factors and Competitive Elimination of Unspecified Cells. English. *Developmental cell* 50.2, 139–154.e5.

1386 Hellen, Christopher U T and Peter Sarnow (2001). Internal ribosome entry sites in eukaryotic mRNA molecules. *Genes
1387 & Development* 15, pp. 1593–1612.

1388 Ho, Patrick and Yvonne Y Chen (2017). Mammalian synthetic biology in the age of genome editing and personalized
1389 medicine. *Current opinion in chemical biology* 40, pp. 57–64.

1390 Hosokawa, Hiroyuki and Ellen V. Rothenberg (2020). How transcription factors drive choice of the T cell fate. *Nature
1391 Reviews Immunology*, pp. 1–15.

1392 Hsiao, Victoria, Emmanuel L.C. De Los Santos, Weston R. Whitaker, John E. Dueber, and Richard M. Murray (2015).
1393 Design and implementation of a biomolecular concentration tracker. *ACS Synthetic Biology* 4.2, pp. 150–161.

1394 Huang, Hsin-Ho, Yili Qian, and Domitilla Del Vecchio (2018). A quasi-integral controller for adaptation of genetic
1395 modules to variable ribosome demand. *Nature Communications* 9, p. 5415.

1396 Huang, Sui, Yan-Ping Guo, Gillian May, and Tariq Enver (2007). Bifurcation dynamics in lineage-commitment in
1397 bipotent progenitor cells. English. *Developmental biology* 305.2, pp. 695–713.

1398 Hussein, Samer M, Nizar N Batada, Sanna Vuoristo, Reagan W Ching, Reija Autio, Elisa Närvä, Siemon Ng, Michel
1399 Sourour, Riikka Hämäläinen, Cia Olsson, Karolina Lundin, Milla Mikkola, Ras Trokovic, Michael Peitz, Oliver
1400 Brüstle, David P Bazett-Jones, Kari Alitalo, Riitta Lahesmaa, Andras Nagy, and Timo Otonkoski (2011). Copy
1401 number variation and selection during reprogramming to pluripotency. English. *Nature* 471.7336, pp. 58–62.

1402 Israni, Divya V, Hui-Shan Li, Keith A Gagnon, Jeffrey D Sander, Kole T Roybal, J Keith Joung, Wilson W Wong, and
1403 Ahmad S Khalil (2021). Clinically-driven design of synthetic gene regulatory programs in human cells, Preprint
1404 at <https://doi.org/10.1101/2021.02.22.432371>.

1405 Ito, Doshun, Hinata Kawamura, Akira Oikawa, Yuta Ihara, Toshio Shibata, Nobuhiro Nakamura, Tsunaki Asano, Shun
1406 Ichiro Kawabata, Takashi Suzuki, and Shinji Masuda (2020). *ppGpp functions as an alarmone in metazoa*.

1407 Jayanthi, Shridhar and Domitilla Del Vecchio (2011). Retroactivity attenuation in bio-molecular systems based on
1408 timescale separation. *IEEE Transactions on Automatic Control* 56.4, pp. 748–761.

1409 Jayanthi, Shridhar, Kayzad Soli Nilgiriwala, and Domitilla Del Vecchio (2013). Retroactivity controls the temporal
1410 dynamics of gene transcription. *ACS Synthetic Biology* 2.8, pp. 431–441.

1411 Johnson, Marion B., Alexander R. March, and Leonardo Morsut (2017). Engineering multicellular systems: Using
1412 synthetic biology to control tissue self-organization. *Current Opinion in Biomedical Engineering* 4, pp. 163–173.

1413 Jones, Ross D., Yili Qian, Katherine Ilia, Benjamin Wang, Michael T. Laub, Domitilla Del Vecchio, and Ron Weiss
1414 (2021). Robust and tunable signal processing in mammalian cells via engineered covalent modification cycles,
1415 Preprint at <https://www.biorxiv.org/content/10.1101/2021.03.30.437779v1>.

1416 Jones, Ross D., Yili Qian, Velia Siciliano, Breanna DiAndreth, Jin Huh, Ron Weiss, and Domitilla Del Vecchio (2020).
1417 An endoribonuclease-based feedforward controller for decoupling resource-limited genetic modules in mammalian
1418 cells. *Nature Communications* 11, p. 5690.

1419 Jopling, Chris, Stephanie Boue, and Juan Carlos Izpisua Belmonte (2011). Dedifferentiation, transdifferentiation and
1420 reprogramming: three routes to regeneration. *Nature Reviews Molecular Cell Biology* 12.2, pp. 79–89.

1421 Jordan, Albert, Patricia Defechereux, and Eric Verdin (2001). The site of HIV-1 integration in the human genome
1422 determines basal transcriptional activity and response to Tat transactivation. *The EMBO Journal* 20.7, pp. 1726–
1423 1738.

1424 Jost, Marco, Daniel A Santos, Reuben A Saunders, Max A Horlbeck, John S Hawkins, Sonia M Scaria, Thomas M
1425 Norman, Jeffrey A Hussmann, Christina R Liem, Carol A Gross, and Jonathan S Weissman (2020). Titrating gene
1426 expression using libraries of systematically attenuated CRISPR guide RNAs. English. *Nature Biotechnology* 6,
1427 e1001154–10.

1428 June, Carl H., Roddy S. O’Connor, Omkar U. Kawalekar, Saba Ghassemi, and Michael C. Milone (2018). CAR T cell
1429 immunotherapy for human cancer. *Science* 359.6382, pp. 1361–1365.

1430 Kauffman, S.A. (1969). Metabolic stability and epigenesis in randomly constructed genetic nets. *Journal of Theoretical*
1431 *Biology* 22.3, pp. 437–467.

1432 Kechschull, Justus M. and Anthony M. Zador (2018). Cellular barcoding: lineage tracing, screening and beyond. *Nature*
1433 *Methods* 15.11, pp. 871–879.

- 1434 Keller, Gordon (2005). Embryonic stem cell differentiation: emergence of a new era in biology and medicine. *Genes*
1435 *& Development* 19.10, pp. 1129–1155.
- 1436 Khalil, Ahmad S and James J Collins (2010). Synthetic biology: applications come of age. English. *Nature reviews.*
1437 *Genetics* 11.5, pp. 367–379.
- 1438 Kiani, Samira, Jacob Beal, Mohammad R. Ebrahimkhani, Jin Huh, Richard N. Hall, Zhen Xie, Yinqing Li, and Ron
1439 Weiss (2014). CRISPR transcriptional repression devices and layered circuits in mammalian cells. *Nature Methods*
1440 11.7, pp. 723–726. arXiv: NIHMS150003.
- 1441 Kim, Tae Kyung and James H. Eberwine (2010). Mammalian cell transfection: the present and the future. *Analytical*
1442 *and Bioanalytical Chemistry* 397.8, pp. 3173–3178.
- 1443 Kinoshita, Ayako Yachie, Kento Onishi, Joel Ostblom, Matthew A Langley, Eszter Posfai, Janet Rossant, and Peter W
1444 Zandstra (2018). Modeling signaling-dependent pluripotency with Boolean logic to predict cell fate transitions.
1445 English. *Molecular systems biology* 14.1, e7952.
- 1446 Kis, Zoltán, Hugo Sant’ Ana Pereira, Takayuki Homma, Ryan M Pedrigi, and Rob Krams (2015). Mammalian synthetic
1447 biology: emerging medical applications. English. *Journal of the Royal Society, Interface / the Royal Society* 12.106,
1448 pp. 20141000–18.
- 1449 Kitaada, Tasuku, Breanna DiAndreth, Brian Teague, and Ron Weiss (Feb. 2018). Programming gene and engineered-
1450 cell therapies with synthetic biology. *Science* 359, eaad1067.
- 1451 Kojima, Ryosuke, Dominique Aubel, and Martin Fussenegger (2020). Building sophisticated sensors of extracellular
1452 cues that enable mammalian cells to work as “doctors” in the body. *Cellular and Molecular Life Sciences*.
- 1453 Kosaka, Nobuyoshi, Hiromi Sakamoto, Masaaki Terada, and Takahiro Ochiya (2009). Pleiotropic function of FGF-4:
1454 Its role in development and stem cells. *Developmental Dynamics* 238.2, pp. 265–276.
- 1455 Krieger, Teresa and Benjamin D. Simons (2015). Dynamic stem cell heterogeneity. *Development* 142.8, pp. 1396–
1456 1406.
- 1457 Laboulaye, Mallory A., Xin Duan, Mu Qiao, Irene E. Whitney, and Joshua R. Sanes (2018). Mapping Transgene
1458 Insertion Sites Reveals Complex Interactions Between Mouse Transgenes and Neighboring Endogenous Genes.
1459 *Frontiers in Molecular Neuroscience* 11, p. 385.
- 1460 Langan, Robert A., Scott E. Boyken, Andrew H. Ng, Jennifer A. Samson, Galen Dods, Alexandra M. Westbrook,
1461 Taylor H. Nguyen, Marc J. Lajoie, Zibo Chen, Stephanie Berger, Vikram Khipple Mulligan, John E. Dueber,
1462 Walter R. P. Novak, Hana El-Samad, and David Baker (2019). De novo design of bioactive protein switches.
1463 *Nature* 572, pp. 205–210.
- 1464 Lawlor, Katerina, Salvador Pérez-Montero, Ana Lima, and Tristan A Rodríguez (2019). Transcriptional versus metabolic
1465 control of cell fitness during cell competition. English. *Seminars in cancer biology*.
- 1466 Lee, Joanne C., Bonnie L. Walton, Catherine A. Hamann, and Jonathan M. Brunger (2020). Synthetic regulation of
1467 multicellular systems for regenerative engineering. *Current Opinion in Biomedical Engineering*, p. 100252.
- 1468 Li, Chuan and Jianzhi Zhang (2019). Stop-codon read-through arises largely from molecular errors and is generally
1469 nonadaptive. *PLOS Genetics* 15.5, e1008141.
- 1470 Li, Pulin, Joseph S. Markson, Sheng Wang, Siheng Chen, Vipul Vachharajani, and Michael B. Elowitz (2018). Mor-
1471 phogen gradient reconstitution reveals Hedgehog pathway design principles. *Science* 0645.April, pp. 1–9.
- 1472 Li, Yinqing, Yun Jiang, He Chen, Weixi Liao, Zhihua Li, Ron Weiss, and Zhen Xie (2015). Modular construction of
1473 mammalian gene circuits using TALE transcriptional repressors. *Nature Chemical Biology* 11, pp. 207–213. arXiv:
1474 NIHMS150003.
- 1475 Liao, Michael J., M Omar Din, Lev Tsimring, and Jeff Hasty (2019). Rock-paper-scissors: Engineered population
1476 dynamics increase genetic stability. *Science* 365, pp. 1045–1049.

- 1477 Liebert, Mary Ann and James Ellis (2005). Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors.
1478 *Human Gene Therapy* 16, pp. 1241–1246.
- 1479 Lienert, Florian, Jason J. Lohmueller, Abhishek Garg, and Pamela A. Silver (2014). Synthetic biology in mam-
1480 malian cells: next generation research tools and therapeutics. English. *Nature Reviews Molecular Cell Biology*
1481 15.2, pp. 95–107.
- 1482 Lillacci, Gabriele, Yaakov Benenson, and Mustafa Khammash (2018). Synthetic control systems for high performance
1483 gene expression in mammalian cells. *Nucleic Acids Research* 46.18, pp. 9855–9863.
- 1484 Lin, Huey, Jami McGrath, Ping Wang, and Techung Lee (2007). Cellular toxicity induced by SRF-mediated transcrip-
1485 tional squelching. *Toxicological Sciences* 96.1, pp. 83–91.
- 1486 Liu, Enze, Lang Li, and Lijun Cheng (2018). Reference Module in Life Sciences, pp. 155–164.
- 1487 Liu, Mingdong, Matthew T. Maurano, Hao Wang, Heyuan Qi, Chao-Zhong Song, Patrick A. Navas, David W. Emery,
1488 John A. Stamatoyannopoulos, and George Stamatoyannopoulos (2015). Genomic discovery of potent chromatin
1489 insulators for human gene therapy. *Nature Biotechnology* 33.2, pp. 198–203.
- 1490 Liu, Ziqing, Olivia Chen, J. Blake Joseph Wall, Michael Zheng, Yang Zhou, Li Wang, Haley Ruth Vaseghi, Li Qian,
1491 and Jiandong Liu (2017). Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector.
1492 *Scientific Reports* 7.1, p. 2193.
- 1493 Lobanova, Ekaterina S., Stella Finkelstein, Nikolai P. Skiba, and Vadim Y. Arshavsky (2013). Proteasome overload is
1494 a common stress factor in multiple forms of inherited retinal degeneration. *PNAS* 110.24, pp. 9986–9991.
- 1495 Loughran, Gary, Ming-Yuan Chou, Ivaylo P. Ivanov, Irwin Jungreis, Manolis Kellis, Anmol M. Kiran, Pavel V. Bara-
1496 nov, and John F. Atkins (2014). Evidence of efficient stop codon readthrough in four mammalian genes. *Nucleic*
1497 *Acids Research* 42.14, pp. 8928–8938.
- 1498 Lund, Riikka J., Elisa Närvä, and Riitta Lahesmaa (2012). Genetic and epigenetic stability of human pluripotent stem
1499 cells. *Nature Reviews Genetics* 13.10, pp. 732–744.
- 1500 Lundh, Stefan, Sayantan Maji, and J. Joseph Melenhorst (2020). Next-generation CAR T cells to overcome current
1501 drawbacks. *International Journal of Hematology* 0123456789.
- 1502 Lyons, Samanthe M., Wenlong Xu, June Medford, and Ashok Prasad (2014). Loads Bias Genetic and Signaling
1503 Switches in Synthetic and Natural Systems. *PLoS Computational Biology* 10.3.
- 1504 Ma, Wenzhe, Ala Trusina, Hana El-Samad, Wendell A. Lim, and Chao Tang (2009). Defining Network Topologies
1505 that Can Achieve Biochemical Adaptation. *Cell* 138.4, pp. 760–773.
- 1506 Ma, Yitong, Mark W. Budde, Michaëlle N. Mayalu, Junqin Zhu, Richard M. Murray, and Michael B. Elowitz (2020).
1507 Synthetic mammalian signaling circuits for robust cell population control, Preprint at <https://doi.org/10.1101/2020.09.02.278564>.
- 1508 Mahon, Matthew J. (2011). Vectors bicistronically linking a gene of interest to the SV40 large T antigen in combi-
1509 nation with the SV40 origin of replication enhance transient protein expression and luciferase reporter activity.
1510 *BioTechniques* 51.2, pp. 119–126.
- 1511 Maldarelli, F., X. Wu, L. Su, F. R. Simonetti, W. Shao, S. Hill, J. Spindler, A. L. Ferris, J. W. Mellors, M. F. Kearney,
1512 J. M. Coffin, and S. H. Hughes (2014). Specific HIV integration sites are linked to clonal expansion and persistence
1513 of infected cells. *Science* 345.6193, pp. 179–183.
- 1514 Mali, Prashant, Luhan Yang, Kevin M Esvelt, John Aach, Marc Guell, James E DiCarlo, Julie E Norville, and George
1515 M Church (2013). RNA-Guided Human Genome Engineering via Cas9. English. *Science* 339.6121, pp. 823–826.
- 1516 Mangan, Shmoolik and Uri Alon (2003). Structure and function of the feed-forward loop network motif. *PNAS* 100.21,
1517 pp. 11980–11985. arXiv: 0711.0685.
- 1518 Martinez, Marina and Edmund Kyung Moon (2019). CAR T cells for solid tumors: New strategies for finding, infil-
1519 trating, and surviving in the tumor microenvironment. *Frontiers in Immunology* 10, p. 128.

1520 Mathur, Melina, Joy S Xiang, and Christina D Smolke (2017). Mammalian synthetic biology for studying the cell.
1521 English. *The Journal of Cell Biology* 216.1, pp. 73–82.

1522 Maze, Alain and Yaakov Benenson (2019). Artificial signaling in mammalian cells enabled by prokaryotic two-
1523 component system. *Nature Chemical Biology* 16, pp. 179–187.

1524 McBride, Cameron and Domitilla Del Vecchio (2017). Analyzing and Exploiting the Effects of Protease Sharing in
1525 Genetic Circuits **This work was supported by AFOSR grant number FA9550-14-1-0060 and NSF Expeditions
1526 in Computing award number 1521925. *IFAC-PapersOnLine* 50.1, pp. 10924–10931.

1527 Menon, Govind and J. Krishnan (2016). Bridging the gap between modules in isolation and as part of networks: A
1528 systems framework for elucidating interaction and regulation of signalling modules. *Journal of Chemical Physics*
1529 145.3.

1530 Merkle, Florian T, Sulagna Ghosh, Nolan Kamitaki, Jana Mitchell, Yishai Avior, Curtis Mello, Seva Kashin, Shila
1531 Mekhoubad, Dusko Ilic, Maura Charlton, Genevieve Saphier, Robert E Handsaker, Giulio Genovese, Shiran Bar,
1532 Nissim Benvenisty, Steven A McCarroll, and Kevin Eggan (2017). Human pluripotent stem cells recurrently ac-
1533 quire and expand dominant negative P53 mutations. English. *Nature Publishing Group* 545.7653, pp. 229–233.

1534 Meyer, Adam J., Thomas H. Segall-Shapiro, Emerson Glassey, Jing Zhang, and Christopher A. Voigt (2019). Es-
1535 cherichia coli “Marionette” strains with 12 highly optimized small-molecule sensors. *Nature Chemical Biology*
1536 15.2, pp. 196–204.

1537 Michaels, Yale S., Mike B. Barnkob, Hector Barbosa, Toni A. Baeumler, Mary K. Thompson, Violaine Andre, Huw
1538 Colin-York, Marco Fritzsche, Uzi Gileadi, Hilary M. Sheppard, David J.H.F. Knapp, Thomas A. Milne, Vincenzo
1539 Cerundolo, and Tudor A. Fulga (2019). Precise tuning of gene expression levels in mammalian cells. *Nature*
1540 *Communications* 10, p. 818.

1541 Milo, R., S. Shen-Orr, S. Itzkovitz, N. Kashtan, D. Chklovskii, and U. Alon (2002). Network Motifs: Simple Building
1542 Blocks of Complex Networks. *Science* 298.5594, pp. 824–827.

1543 Mishra, Deepak, Phillip M. Rivera, Allen Lin, Domitilla Del Vecchio, and Ron Weiss (2014). A load driver device for
1544 engineering modularity in biological networks. *Nature Biotechnology* 32.12, pp. 1268–1275.

1545 Mitchell, Rick S, Brett F Beitzel, Astrid R. W Schroder, Paul Shinn, Huaming Chen, Charles C Berry, Joseph R Ecker,
1546 and Frederic D Bushman (2004). Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site
1547 Preferences. *PLoS Biology* 2.8, e234.

1548 Moiani, Arianna, Ylenia Paleari, Daniela Sartori, Riccardo Mezzadra, Annarita Miccio, Claudia Cattoglio, Fabienne
1549 Cocchiarella, Maria Rosa Lidonnici, Giuliana Ferrari, and Fulvio Mavilio (2012). Lentiviral vector integration in
1550 the human genome induces alternative splicing and generates aberrant transcripts. *Journal of Clinical Investigation*
1551 122.5, pp. 1653–1666.

1552 Morsut, Leonardo, Kole T. Roybal, Xin Xiong, Russell M. Gordley, Scott M. Coyle, Matthew Thomson, and Wendell
1553 A. Lim (2016). Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.
1554 *Cell* 164.4, pp. 780–791.

1555 Müller-Kuller, Uta, Mania Ackermann, Stephan Kolodziej, Christian Brendel, Jessica Fritsch, Nico Lachmann, Hana
1556 Kunkel, Jörn Lausen, Axel Schambach, Thomas Moritz, and Manuel Grez (2015). A minimal ubiquitous chro-
1557 matin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic
1558 remodeling in multipotent and pluripotent stem cells. English. *Nucleic acids research* 43.3, pp. 1577–1592.

1559 Müller, Isaak E., Jacob R. Rubens, Tomi Jun, Daniel Graham, Ramnik Xavier, and Timothy K. Lu (2019). Gene
1560 networks that compensate for crosstalk with crosstalk. *Nature Communications* 10, p. 4028.

1561 Munding, Elizabeth M., Lily Shiue, Sol Katzman, JohnPaul Donohue, and Manuel Ares (2013). Competition between
1562 Pre-mRNAs for the splicing machinery drives global regulation of splicing. *Molecular Cell* 51.3, pp. 338–348.

1563 Nayerossadat, Nouri, Talebi Maedeh, and Palizban Abas Ali (2012). Viral and nonviral delivery systems for gene
1564 delivery. *Advanced Biomedical Research* 1.1, p. 27.

1565 Nevozhay, Dmitry, Rhys M. Adams, Kevin F. Murphy, K. Josic, and G. Balazsi (2009). Negative autoregulation
1566 linearizes the dose-response and suppresses the heterogeneity of gene expression. *PNAS* 106.13, pp. 5123–5128.
1567 arXiv: arXiv:1408.1149.

1568 Nevozhay, Dmitry, Tomasz Zal, and Gábor Balázsi (2013). Transferring a synthetic gene circuit from yeast to mam-
1569 malian cells. *Nature Communications* 4, p. 1451. arXiv: 9809069v1 [arXiv:gr-qc].

1570 Ng, Andrew H., Taylor H. Nguyen, Mariana Gómez-Schiavon, Galen Dods, Robert A. Langan, Scott E. Boyken,
1571 Jennifer A. Samson, Lucas M. Waldburger, John E. Dueber, David Baker, and Hana El-Samad (2019). Modular
1572 and tunable biological feedback control using a de novo protein switch. *Nature* 572.7768, pp. 265–269.

1573 Nicola, N A (1994). Cytokine pleiotropy and redundancy: a view from the receptor. *Stem cells (Dayton, Ohio)* 12
1574 Suppl 1, 3–12, discussion 12–4.

1575 Nilgiriwala, Kayzad Soli, José Jiménez, Phillip Michael Rivera, and Domitilla Del Vecchio (2015). Synthetic Tunable
1576 Amplifying Buffer Circuit in *E. coli*. *ACS Synthetic Biology* 4.5, pp. 577–584.

1577 Nissim, Lior, Samuel D. Perli, Alexandra Fridkin, Pablo Perez-Pinera, and Timothy K. Lu (2014). Multiplexed and
1578 Programmable Regulation of Gene Networks with an Integrated RNA and CRISPR/Cas Toolkit in Human Cells.
1579 *Molecular Cell* 54, pp. 698–710.

1580 Nobles, Christopher L, Scott Sherrill-Mix, John K Everett, Shantan Reddy, Joseph A Fraietta, David L Porter, Noelle
1581 Frey, Saar I Gill, Stephan A Grupp, Shannon L Maude, Donald L Siegel, Bruce L Levine, Carl H June, Simon
1582 F Lacey, J Joseph Melenhorst, and Frederic D Bushman (2019). CD19-targeting CAR T cell immunotherapy
1583 outcomes correlate with genomic modification by vector integration. English. *The Journal of Clinical Investigation*
1584 3.95, p. 51.

1585 Nunns, Harry and Lea Goentoro (2018). Signaling pathways as linear transmitters. *eLife* 7, e33617.

1586 Olsman, Noah, Ania-Ariadna Baetica, Fangzhou Xiao, Yoke Peng Leong, Richard M. Murray, and John C. Doyle
1587 (2019). Hard Limits and Performance Tradeoffs in a Class of Antithetic Integral Feedback Networks. *Cell Systems*
1588 9.1, pp. 49–63.

1589 Pantoja-Hernández, Libertad and Juan Carlos Martínez-García (2015). Retroactivity in the Context of Modularly
1590 Structured Biomolecular Systems. *Frontiers in Bioengineering and Biotechnology* 3.June, pp. 1–16.

1591 Papapetrou, Eirini P and Axel Schambach (2016). Gene Insertion Into Genomic Safe Harbors for Human Gene Ther-
1592 apy. *Molecular Therapy* 24.4, pp. 678–684.

1593 Park, Minhee, Nikit Patel, Albert J. Keung, and Ahmad S. Khalil (2019). Engineering Epigenetic Regulation Using
1594 Synthetic Read-Write Modules. *Cell* 176.1-2, 227–238.e20.

1595 Perli, Samuel D, Cheryl H Cui, and Timothy K Lu (2016). Continuous genetic recording with self-targeting CRISPR-
1596 Cas in human cells. English. *Science* 353.6304.

1597 Perteau, Mihaela, Alaina Shumate, Geo Perteau, Ales Varabyou, Florian P. Breitwieser, Yu-Chi Chang, Anil K. Madugundu,
1598 Akhilesh Pandey, and Steven L. Salzberg (2018). CHESS: a new human gene catalog curated from thousands of
1599 large-scale RNA sequencing experiments reveals extensive transcriptional noise. *Genome Biology* 19.1, p. 208.

1600 Plath, Kathrin and William E. Lowry (2011). Progress in understanding reprogramming to the induced pluripotent
1601 state. *Nature Reviews Genetics* 12.4, pp. 253–265.

1602 Ponjavic, Jasmina, Boris Lenhard, Chikatoshi Kai, Jun Kawai, Piero Carninci, Yoshihide Hayashizaki, and Albin
1603 Sandelin (2006). Transcriptional and structural impact of TATA-initiation site spacing in mammalian core promot-
1604 ers. *Genome biology* 7.8, R78.

1605 Prabakaran, Sudhakaran, Guy Lippens, Hanno Steen, and Jeremy Gunawardena (2012). Post-translational modifica-
1606 tion: Nature’s escape from genetic imprisonment and the basis for dynamic information encoding. *Wiley Interdis-*
1607 *ciplinary Reviews: Systems Biology and Medicine* 4.6, pp. 565–583.

1608 Prasad, K-M R, Y Xu, Z Yang, S T Acton, and B A French (2011). Robust cardiomyocyte-specific gene expression
1609 following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. *Gene Therapy* 18.1,
1610 pp. 43–52.

1611 Prochazka, Laura, Bartolomeo Angelici, Benjamin Haefliger, and Yaakov Benenson (2014). Highly modular bow-tie
1612 gene circuits with programmable dynamic behaviour. English. *Nature communications* 5, p. 4729.

1613 Prochazka, Laura, Yaakov Benenson, and Peter W Zandstra (2017). Synthetic gene circuits and cellular decision-
1614 making in human pluripotent stem cells. English. *Current Opinion in Systems Biology* 5, pp. 93–103.

1615 Proudfoot, Nick J. (2016). Transcriptional termination in mammals: Stopping the RNA polymeraseII juggernaut. *Sci-*
1616 *ence* 352.6291, aad9926.

1617 Qian, Yili and Domitilla Del Vecchio (2018). Realizing “Integral Control” In Living Cells: How To Overcome Leaky
1618 Integration Due To Dilution? *Journal of The Royal Society Interface* 15, p. 20170902.

1619 — (2019). A singular singular perturbation problem arising from a class of biomolecular feedback controllers. *IEEE*
1620 *Control Systems Letters* 3.2, pp. 236–241.

1621 Qian, Yili, Hsin Ho Huang, José I. Jiménez, and Domitilla Del Vecchio (2017). Resource Competition Shapes the
1622 Response of Genetic Circuits. *ACS Synthetic Biology* 6.7, pp. 1263–1272.

1623 Quarton, Tyler, Taek Kang, Vasileios Papakis, Khai Nguyen, Chance Nowak, Yi Li, and Leonidas Bleris (2020).
1624 Uncoupling gene expression noise along the central dogma using genome engineered human cell lines. *Nucleic*
1625 *acids research* 48.16, pp. 9406–9413.

1626 Raffin, Caroline, Linda T. Vo, and Jeffrey A. Bluestone (2020). Treg cell-based therapies: challenges and perspectives.
1627 *Nature Reviews Immunology* 20.3, pp. 158–172.

1628 Rafiq, Sarwish, Christopher S. Hackett, and Renier J. Brentjens (2020). Engineering strategies to overcome the current
1629 roadblocks in CAR T cell therapy. *Nature Reviews Clinical Oncology* 17.3, pp. 147–167.

1630 Raser, Jonathan M. and Erin K. O’Shea (2005). Noise in Gene Expression: Origins, Consequences, and Control.
1631 *Science* 309.5743, pp. 2010–2013.

1632 Rauch, Simone, Krysten A. Jones, and Bryan Dickinson (2020). Small Molecule-Inducible RNA-Targeting Systems
1633 for Temporal Control of RNA Regulation.

1634 Rayon, Teresa, Despina Stamataki, Ruben Perez-Carrasco, Lorena Garcia-Perez, Christopher Barrington, Manuela
1635 Melchiond, Katherine Exelby, Jorge Lazaro, Victor L. J. Tybulewicz, Elizabeth M. C. Fisher, and James Briscoe
1636 (2020). Species-specific pace of development is associated with differences in protein stability. *Science* 369,
1637 eaba7667.

1638 Rezania, Alireza, Jennifer E Bruin, Payal Arora, Allison Rubin, Irina Batushansky, Ali Asadi, Shannon O’Dwyer,
1639 Nina Quiskamp, Majid Mojibian, Tobias Albrecht, Yu Hsuan Carol Yang, James D Johnson, and Timothy J Kieffer
1640 (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nature*
1641 *Biotechnology* 32.11, pp. 1121–1133.

1642 Rowland, Michael A, Walter Fontana, and Eric J Deeds (2012). Crosstalk and Competition in Signaling Networks.
1643 *Biophysj* 103.11, pp. 2389–2398.

1644 Rutherford, Karen and Gregory D. Van Duyne (2014). The ins and outs of serine integrase site-specific recombination.
1645 *Current Opinion in Structural Biology* 24.1, pp. 125–131.

1646 Ryder, Pearl V. and Dorothy A. Lerit (2018). RNA localization regulates diverse and dynamic cellular processes.
1647 *Traffic* 19.7, pp. 496–502.

1648 Sabi, Renana and Tamir Tuller (2019). Modelling and measuring intracellular competition for finite resources during
1649 gene expression. *Journal of the Royal Society Interface* 16, p. 20180887.

1650 Sánchez-Cuenca, Jaime, Julio C Martín, Antonio Pellicer, and Carlos Simón (1999). Cytokine pleiotropy and redun-
1651 dancy – gp130 cytokines in human implantation. *Immunology Today* 20.2, pp. 57–59.

1652 Sancho, Margarida, Aida Di-Gregorio, Nancy George, Sara Pozzi, Juan Miguel Sánchez, Barbara Pernaute, and Tristan
1653 A Rodríguez (2013). Competitive interactions eliminate unfit embryonic stem cells at the onset of differentiation.
1654 English. *Developmental cell* 26.1, pp. 19–30.

1655 Satyanarayana, A and P Kaldis (2009). Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse
1656 compensatory mechanisms. *Oncogene* 28.33, pp. 2925–2939.

1657 Scheller, Leo and Martin Fussenegger (2019). From synthetic biology to human therapy: engineered mammalian cells.
1658 *Current Opinion in Biotechnology* 58, pp. 108–116.

1659 Scheller, Leo, Marc Schmollack, Adrian Bertschi, Maysam Mansouri, Pratik Saxena, and Martin Fussenegger (2020).
1660 Phosphoregulated orthogonal signal transduction in mammalian cells. *Nature Communications* 11.1, p. 3085.

1661 Schmidt, Florian, Mariia Y Cherepkova, and Randall J Platt (2018). Transcriptional recording by CRISPR spacer
1662 acquisition from RNA. *Nature*, pp. 1–23.

1663 Schubert, Peter, Klaus Pfeleiderer, and Wolfgang Hillen (2004). Tet repressor residues indirectly recognizing anhy-
1664 drotetracycline. *European Journal of Biochemistry* 271.11, pp. 2144–2152.

1665 Schukur, Lina, Barbara Geering, Ghislaine Charpin-El Hamri, and Martin Fussenegger (2015). Implantable synthetic
1666 cytokine converter cells with AND-gate logic treat experimental psoriasis. *Science Translational Medicine*.

1667 Schwanhäusser, Björn, Dorothea Busse, Na Li, Gunnar Dittmar, Johannes Schuchhardt, Jana Wolf, Wei Chen, and
1668 Matthias Selbach (2011). Global quantification of mammalian gene expression control. *Nature* 473.7347, pp. 337–
1669 342.

1670 Segall-Shapiro, Thomas H., Eduardo D. Sontag, and Christopher A. Voigt (2018). Engineered promoters enable con-
1671 stant gene expression at any copy number in bacteria. *Nature Biotechnology* 36.4, pp. 352–358.

1672 Sevier, Stuart A. and Herbert Levine (2018). Properties of gene expression and chromatin structure with mechanically
1673 regulated elongation. *Nucleic Acids Research* 46.12, pp. 5924–5934.

1674 Shah, Nirali N, Haiying Qin, Bonnie Yates, Ling Su, Haneen Shalabi, Mark Raffeld, Mark A Ahlman, Maryalice
1675 Stetler-Stevenson, Constance Yuan, Shuang Guo, Siyuan Liu, Stephen H Hughes, Terry J Fry, and Xiaolin Wu
1676 (2019). Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22
1677 CAR T-cell therapy. English. *Blood Advances* 3.15, pp. 2317–2322.

1678 Shakiba, Nika, Ahmed Fahmy, Gowtham Jayakumar, Sophie McGibbon, Laurent David, Daniel Trcka, Judith Elbaz,
1679 Mira C Puri, Andras Nagy, Derek van der Kooy, Sidhartha Goyal, Jeffrey L Wrana, and Peter W Zandstra (2019).
1680 Cell competition during reprogramming gives rise to dominant clones. English. *Science* 364.6438, eaan0925–11.

1681 Shakiba, Nika and Peter W Zandstra (2017). Engineering cell fitness: lessons for regenerative medicine. English.
1682 *Current opinion in biotechnology* 47, pp. 7–15.

1683 Sheth, Ravi U, Sung Sun Yim, Felix L Wu, and Harris H Wang (2017). Multiplex recording of cellular events over
1684 time on CRISPR biological tape. English. *Science* 358.6369, pp. 1457–1461.

1685 Shopera, Tatenda, Lian He, Tolutola Oyetunde, Yinjie J. Tang, and Tae Seok Moon (2017). Decoupling Resource-
1686 Coupled Gene Expression in Living Cells. *ACS Synthetic Biology* 6, pp. 1596–1604.

1687 Shoval, Oren, Uri Alon, and Eduardo Sontag (2011). Symmetry invariance for adapting biological systems. *SIAM*
1688 *Journal on Applied Dynamical Systems* 10.3, pp. 857–886. arXiv: 1012.2782.

1689 Singh, Digvijay, Samuel H. Sternberg, Jingyi Fei, Taekjip Ha, and Jennifer A. Doudna (2016). Real-time observation
1690 of DNA recognition and rejection by the RNA-guided endonuclease Cas9. *Nature Communications* 7, p. 12778.

1691 Smith, Caitlin (2007). Transposons: cut-and-paste gene delivery. *Nature Methods* 4.2, pp. 183–186.

1692 Stanton, Brynne C., Velia Siciliano, Amar Ghodasara, Liliana Wroblewska, Kevin Clancy, Axel C. Trefzer, Jonathan
1693 D. Chesnut, Ron Weiss, and Christopher A. Voigt (Dec. 2014). Systematic transfer of prokaryotic sensors and
1694 circuits to mammalian cells. *ACS Synthetic Biology* 3, pp. 880–891.

1695 Stapleton, James A., Kei Endo, Yoshihiko Fujita, Karin Hayashi, Masahiro Takinoue, Hirohide Saito, and Tan Inoue
1696 (2012). Feedback control of protein expression in mammalian cells by tunable synthetic translational inhibition.
1697 *ACS Synthetic Biology* 1.3, pp. 83–88.

1698 Staunstrup, Nicklas H, Brian Moldt, Lajos Mátés, Palle Villesen, Maria Jakobsen, Zoltán Ivics, Zsuzsanna Izsvák,
1699 and Jacob Giehm Mikkelsen (2009). Hybrid Lentivirus-transposon Vectors With a Random Integration Profile in
1700 Human Cells. *Molecular Therapy* 17.7, pp. 1205–1214.

1701 Steel, Harrison, Aivar Sootla, Nicolas Delalez, and Antonis Papachristodoulou (2019). Mitigating biological signalling
1702 cross-talk with feedback control. *2019 18th European Control Conference, ECC 2019*, pp. 2638–2643.

1703 Strebinger, Daniel, Cédric Deluz, Elias T. Friman, Subashika Govindan, Andrea B. Alber, and David M. Suter (2019).
1704 Endogenous fluctuations of OCT4 and SOX2 bias pluripotent cell fate decisions. *Molecular Systems Biology* 15,
1705 e9002.

1706 Strovas, Timothy J., Alexander B. Rosenberg, Brianna E. Kuypers, Richard A. Muscat, and Georg Seelig (2014).
1707 MicroRNA-Based Single-Gene Circuits Buffer Protein Synthesis Rates against Perturbations. *ACS Synthetic Biol-*
1708 *ogy* 3, pp. 324–331.

1709 Sturm, Oliver E., Richard Orton, Joan Grindlay, Marc Birtwistle, Vladislav Vyshemirsky, David Gilbert, Muffy Calder,
1710 Andrew Pitt, Boris Kholodenko, and Walter Kolch (2010). The mammalian MAPK/ERK pathway exhibits prop-
1711 erties of a negative feedback amplifier. *Science Signaling* 3.153, ra90.

1712 Szenk, Mariola, Terrence Yim, and Gábor Balázs (2020). Multiplexed Gene Expression Tuning with Orthogonal
1713 Synthetic Gene Circuits. *ACS Synthetic Biology* 9.4, pp. 930–939.

1714 Szymczak, Andrea L., Creg J. Workman, Yao Wang, Kate M. Vignali, Smaroula Dilioglou, Elio F. Vanin, and Dario
1715 A.A. Vignali (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based
1716 retroviral vector. *Nature Biotechnology* 22.5, pp. 589–594.

1717 Takahashi, K and S Yamanaka (2006). Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibrobl-
1718 last Cultures by Defined Factors. *Cell* 126.4. Cited By (since 1996): 1950 Export Date: 18 October 2010 Source:
1719 Scopus, pp. 663–676.

1720 Takahashi, Kazutoshi and Shinya Yamanaka (2016). A decade of transcription factor-mediated reprogramming to
1721 pluripotency. English. *Nature Reviews Molecular Cell Biology* 17.3, pp. 183–193.

1722 Tang, Weixin and David R Liu (2018). Rewritable multi-event analog recording in bacterial and mammalian cells.
1723 English. *Science* 360.6385, eaap8992–12.

1724 Teague, Brian P., Patrick Guye, and Ron Weiss (2016). Synthetic morphogenesis. *Cold Spring Harbor Perspectives in*
1725 *Biology* 8.9, pp. 1–16.

1726 Teshigawara, Rika, Junkwon Cho, Masahiro Kameda, and Takashi Tada (2017). Mechanism of human somatic repro-
1727 gramming to iPS cell. *Laboratory Investigation* 97.10, pp. 1152–1157.

1728 Tewary, Mukul, Nika Shakiba, and Peter W Zandstra (2018). Stem cell bioengineering: building from stem cell biol-
1729 ogy. English. *Nature reviews. Genetics* 14, pp. 1–20.

1730 Thakore, Pratiksha I, Joshua B Black, Isaac B Hilton, and Charles A Gersbach (2016). Editing the epigenome: tech-
1731 nologies for programmable transcription and epigenetic modulation. *Nature Methods* 13.2, pp. 127–137.

1732 Toda, Satoshi, Nicholas W. Frankel, and Wendell A. Lim (2019). Engineering cell–cell communication networks:
1733 programming multicellular behaviors. *Current Opinion in Chemical Biology* 52, pp. 31–38.

1734 Tong, Wilbur, Olga I. Kulaeva, David J. Clark, and Leonard C. Lutter (2006). Topological Analysis of Plasmid Chromatin from Yeast and Mammalian Cells. *Journal of Molecular Biology* 361.5, pp. 813–822.

1735

1736 Tonge, Peter D, Andrew J Corso, Claudio Monetti, Samer M I Hussein, Mira C Puri, Iacovos P Michael, Mira Li, Dong-Sung Lee, Jessica C Mar, Nicole Cloonan, David L Wood, Maely E Gauthier, Othmar Korn, Jennifer L Clancy, Thomas Preiss, Sean M Grimmond, Jong-Yeon Shin, Jeong-Sun Seo, Christine A Wells, Ian M Rogers, and Andras Nagy (2014). Divergent reprogramming routes lead to alternative stem-cell states. *Nature* 516.7530, pp. 192–197.

1737

1738

1739

1740

1741 Trauth, Jonathan, Johannes Scheffer, Sophia Hasenjäger, and Christof Taxis (2019). Synthetic Control of Protein Degradation during Cell Proliferation and Developmental Processes. *ACS Omega* 4.2, pp. 2766–2778.

1742

1743 Tsankov, Alexander M., Hongcang Gu, Veronika Akopian, Michael J. Ziller, Julie Donaghey, Ido Amit, Andreas Gnirke, and Alexander Meissner (2015). Transcription factor binding dynamics during human ES cell differentiation. *Nature* 518.7539, pp. 344–349.

1744

1745

1746 Veliz-Cuba, Alan, Andrew J. Hirning, Adam A. Atanas, Faiza Hussain, Flavia Vancia, Krešimir Josić, and Matthew R. Bennett (2015). Sources of Variability in a Synthetic Gene Oscillator. *PLoS Computational Biology* 11.12, e1004674.

1747

1748

1749 Vranckx, Lenard S., Jonas Demeulemeester, Zeger Debyser, and Rik Gijsbers (2016). Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras. *PLOS ONE* 11.10, e0164167.

1750

1751 Waddington, Conrad Hal (1957). *The strategy of the genes*. English. Allen & Unwin. Allen & Unwin.

1752 Wagner, Thor A., Sherry McLaughlin, Kavita Garg, Charles Y. K. Cheung, Brendan B. Larsen, Sheila Styrchak, Hannah C. Huang, Paul T. Edlfsen, James I. Mullins, and Lisa M. Frenkel (2014). Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. *Science* 345.6196, pp. 570–573.

1753

1754

1755 Wagner, Tyler E., Jacob R. Becraft, Katie Bodner, Brian Teague, Xin Zhang, Amanda Woo, Ely Porter, Bremy Alburquerque, Brian Dobosh, Oliwia Andries, Niek N. Sanders, Jacob Beal, Douglas Densmore, Tasuku Kitada, and Ron Weiss (2018). Small-molecule-based regulation of RNA-delivered circuits in mammalian cells. *Nature Chemical Biology* 14.11, pp. 1043–1050.

1756

1757

1758

1759 Wahlfors, J. J., S. A. Zullo, S. Loimas, D. M. Nelson, and R. A. Morgan (2000). Evaluation of recombinant alphaviruses as vectors in gene therapy. *Gene Therapy* 7.6, pp. 472–480.

1760

1761 Weinberg, Benjamin H, N T Hang Pham, Leidy D Caraballo, Thomas Lozanoski, Adrien Engel, Swapnil Bhatia, and Wilson W Wong (2017). Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells. *Nature Biotechnology* 35.5, pp. 453–462.

1762

1763

1764 Weinreb, Caleb, Alejo Rodriguez-Fraticelli, Fernando D Camargo, and Allon M Klein (2020). Lineage tracing on transcriptional landscapes links state to fate during differentiation. English. *Science* 367.6479, eaaw3381–11.

1765

1766 West, Adam G., Miklos Gaszner, and Gary Felsenfeld (2002). Insulators: many functions, many mechanisms. *Genes & Development* 16.3, pp. 271–288.

1767

1768 Wilkinson, Darren J. (2009). Stochastic modelling for quantitative description of heterogeneous biological systems. *Nature Reviews Genetics* 10.2, pp. 122–133.

1769

1770 Williams, Luis A., Brandi N. Davis-Dusenbery, and Kevin C. Eggan (2012). SnapShot: Directed Differentiation of Pluripotent Stem Cells. *Cell* 149.5, 1174–1174.e1.

1771

1772 Wroblewska, Liliana, Tasuku Kitada, Kei Endo, Velia Siciliano, Breanna Stillo, Hirohide Saito, and Ron Weiss (2015). Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. *Nature Biotechnology* 33.8, pp. 839–841.

1773

1774

1775 Xie, Mingqi and Martin Fussenegger (2015). Mammalian designer cells: Engineering principles and biomedical applications. English. *Biotechnology journal* 10.7, 10051018–n/a.

1776

1777 Xie, Mingqi, Haifeng Ye, Hui Wang, Ghislaine Charpin-el Hamri, Claude Lormeau, Pratik Saxena, and Martin Fusseneg-
1778 ger (2016). b-cell-mimetic designer cells provide closed-loop glycemic control. *Science* 354.6317, pp. 1296–1301.

1779 Xie, Zhen, Liliana Wroblewska, Laura Prochazka, Ron Weiss, and Yaakov Benenson (2011). Multi-Input RNAi-Based
1780 Logic Circuit for Identification of Specific Cancer Cells. *Science* 333, pp. 1307–1311.

1781 Yamaguchi, Shige-yuki, Yasuhiro Kazuki, Yuji Nakayama, Eiji Nanba, Mitsuo Oshimura, and Tetsuya Ohbayashi
1782 (2011). A method for producing transgenic cells using a multi-integrase system on a human artificial chromo-
1783 some vector. *PLoS ONE* 6.2, e17267.

1784 Yan, Koon-Kiu, Daifeng Wang, Anurag Sethi, Paul Muir, Robert Kitchen, Chao Cheng, and Mark Gerstein (2016).
1785 Cross-Disciplinary Network Comparison: Matchmaking between Hairballs. *Cell Systems* 2.3, pp. 147–157.

1786 Yant, Stephen R., Xiaolin Wu, Yong Huang, Brian Garrison, Shawn M. Burgess, and Mark A. Kay (2005). High-
1787 Resolution Genome-Wide Mapping of Transposon Integration in Mammals. *Molecular and Cellular Biology* 25.6,
1788 pp. 2085–2094.

1789 Ye, Haifeng, Mingqi Xie, Shuai Xue, Ghislaine Charpin-El Hamri, Jianli Yin, Henryk Zulewski, and Martin Fusseneg-
1790 ger (2016). Self-adjusting synthetic gene circuit for correcting insulin resistance. *Nature Biomedical Engineering*
1791 1, p. 0005.

1792 Yeung, Enoch, Aaron J. Dy, Kyle B. Martin, Andrew H. Ng, Domitilla Del Vecchio, James L. Beck, James J. Collins,
1793 and Richard M. Murray (2017). Biophysical Constraints Arising from Compositional Context in Synthetic Gene
1794 Networks. *Cell Systems* 5.1, pp. 11–24.

1795 Yi, T.-M., Y. Huang, M. I. Simon, and J. Doyle (Apr. 2000). Robust perfect adaptation in bacterial chemotaxis through
1796 integral feedback control. *PNAS* 97.9, pp. 4649–4653.

1797 Yokobayashi, Yohei (2019). Aptamer-based and aptazyme-based riboswitches in mammalian cells. *Current Opinion*
1798 *in Chemical Biology* 52, pp. 72–78.

1799 Yosef, Nir and Aviv Regev (2011). Impulse Control: Temporal Dynamics in Gene Transcription. *Cell* 144.6, pp. 886–
1800 896.

1801 Youk, Hyun and Wendell A Lim (2014). Secreting and sensing the same molecule allows cells to achieve versatile
1802 social behaviors. *Science* 343.6171, p. 1242782.

1803 Zechner, Christoph, Elisa Nerli, and Caren Norden (2020). Stochasticity and determinism in cell fate decisions. *De-*
1804 *velopment* 147.14, dev181495.

1805 Zhang, Qiang, Sudin Bhattacharya, and Melvin E Andersen (2013). Ultrasensitive response motifs: basic amplifiers in
1806 molecular signalling networks. *Open Biology* 3 VN - re.4, p. 130031.

1807 Zhang, Shuyi and Christopher A. Voigt (2018). Engineered dCas9 with reduced toxicity in bacteria: implications for
1808 genetic circuit design. *Nucleic Acids Research* 46.20, pp. 11115–11125.

1809 Zhao, Wei, Anhua Lei, Lin Tian, Xudong Wang, Cristina Correia, Taylor Weiskittel, Hu Li, Alan Trounson, Qiuli Fu,
1810 Ke Yao, and Jin Zhang (2020). Strategies for Genetically Engineering Hypoimmunogenic Universal Pluripotent
1811 Stem Cells. *iScience* 23.6, pp. 1–9.

1812 Zhou, Joseph X. and Sui Huang (2011). Understanding gene circuits at cell-fate branch points for rational cell repro-
1813 gramming. *Trends in Genetics* 27.2, pp. 55–62.

1814 Zhu, Wenliang, Boya Zhang, Mengqi Li, Fan Mo, Tingwei Mi, Yihui Wu, Zhaoqian Teng, Qi Zhou, Wei Li, and
1815 Baoyang Hu (2019). Precisely controlling endogenous protein dosage in hPSCs and derivatives to model FOXG1
1816 syndrome. *Nature Communications* 10.1.

1817 Zhu, Zengrong and Danwei Huangfu (2013). Human pluripotent stem cells: an emerging model in developmental
1818 biology. *Development* 140.4, pp. 705–717.

1819 Zopf, C. J., Katie Quinn, Joshua Zeidman, and Narendra Maheshri (2013). Cell-Cycle Dependence of Transcription
1820 Dominates Noise in Gene Expression. *PLoS Computational Biology* 9.7, e1003161.